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Over the past decade, the number of genome-wide association studies (GWAS) carried out has 
increased exponentially. These studies, mostly by investigating single nucleotide polymorphisms 
(SNPs), have discovered thousands of new loci associated to numerous complex diseases and 
traits, such as Crohn’s Disease, Type-1 and Type-2 diabetes, height and body mass index. 
Unfortunately, there are several limitations to current GWAS. Firstly these newly discovered 
associations fail to explain all of the observed phenotypic variability attributed to genetic 
sources. This issue of missing heritability can be attributed to multiple sources such as rare 
variants, epigenetics and gene-gene interactions. Secondly, the majority of GWAS have not 
investigated the contribution of the sex chromosomes to complex disease. And thirdly, though 
comorbidity studies have well-established the overlap between some diseases, many initial 
GWAS focused on single phenotypes, and are only recently investigating the genetic overlap 
between various complex diseases (and traits). Here, we investigate and extend various aspects 
of GWAS to address these issues. First, we investigate the implication of rare or low frequency 
causal variants (SNPs with a minor allele frequency <5%) for GWAS and find that when 
diseases are caused by (unassayed) rare variants, the associated SNPs tend to lie further away 
than expected when diseases are caused by common variants. Second, we investigate the role of 
chromosome X in complex disease. The X chromosome was routinely ignored and mishandled in 
many GWAS, thus possibly explaining the lack of X-linked associations. Hence, we developed 
an X-tailored pipeline and applied it to 16 datasets of autoimmune and immune-mediated 
disorders. We found several genes implicated in disease risk, some of which have sex-
differentiated function. Finally, we developed a novel method, disPCA, that uses principal 
component analysis to investigate the shared genetics between various complex diseases and 
traits. Applying disPCA to 31 GWAS datasets, we found several pathways that may underlie 
shared pathogenesis between distinct diseases and traits. Though genotyping-based GWAS are 
being quickly replaced with sequencing-based association studies, the conclusions and tools 
developed here can also be applied to this new generation of data.  
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Chapter 1：  Introduction 
 
 
The rapid decline in cost of assaying genetic information ushered in the era of genome-wide 
association studies (GWAS). In its simplest form, GWAS consists of comparing genetic 
information at different loci between individuals with a disease (cases) and those without 
(controls). Usually assayed at single nucleotide polymorphisms (SNPs), associated SNPs 
represent a significant correlation between case or control status and the SNP itself. GWAS are 
also carried out on quantitative phenotypes, such as height, in a similar fashion. Associations do 
not necessarily point to causality though, as SNPs assayed by genotyping arrays serve as tag 
markers for other SNPs or different types of variants that they are correlated with, i.e. within the 
same linkage disequilibrium (LD) block. Thus other untyped variants within the same LD block 
as an associated SNP may be the true underlying genetic variant/s.  
 
Over the past decade, over 1350 studies have been reported (Hindorff, MacArthur et al. 2013) 
with over 11,000 associated SNPs (Welter, MacArthur et al. 2014). Each association holds 
promise for narrowing the search field for disease mechanisms and options for treatment. For 
example, the association of complement factor H to age-related macular degeneration is now 
being investigated as a therapeutic target for the disease (Troutbeck, Al-Qureshi et al. 2012). In 
essence, GWAS serve as one possible initial step to understanding the biology of diseases that 
can further advance medicine and eventually lead to effective measures of healthcare (Green and 
Guyer 2011).  
 
Despite this aforementioned promise and projected success, early GWAS were limited and were 
expanded to address the following issues: 1) the case of missing heritability 2) exploring the 
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contribution of chromosome X and 3) the focus on single phenotypes. Firstly it was surprising to 
find that discovered associations had yet to explain a significant portion of genetic variability for 
many traits and disease risks (the problem of missing heritability) (Manolio, Collins et al. 2009). 
It was postulated that there were genetic variants and types of associations that conventional 
GWAS data and methods missed. These included epigenetics, genetic interactions, structural 
variants and low frequency variants (variants with minor allele frequency –MAF<0.05). The case 
of rare or low frequency variants was particularly troublesome as one study suggested that if rare 
variants underlay signals of association (the case of “synthetic associations”), then the actual 
causal variants could be much further away from an association signal than expected given 
common causal variants (Dickson, Wang et al. 2010). This in turn could suggest that fine 
mapping studies (studies following up GWAS to narrow down the causal locus behind an 
association signal) needed to explore a larger genomic area to find the actual causal variant 
underlying an association. While the results presented in Dickson et al. suggested reevaluating 
fine mapping strategies, the study based their results on simulated data. In order to better 
understand the phenomenon of synthetic associations though, one would need to explore the 
phenomenon in human genetic data with actual patterns of LD between common and rare 
variants. Thus, using such data I refined our expectations regarding synthetic associations 
(Chapter 2).  
 
Another potential source of missing heritability is the X chromosome. In humans, females have 
two copies of the X chromosome, while males have one. It has been suggested that chromosome 
X may play a role in sex-specific disorders and diseases such as many autoimmune disorders 
(Ober, Loisel et al. 2008; Libert, Dejager et al. 2010; Bianchi, Lleo et al. 2011; Quintero, 
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Amador-Patarroyo et al. 2012; Selmi, Brunetta et al. 2012), and it is also implicated in some 
Mendelian disorders (Hamosh, Scott et al. 2002; Hamosh, Scott et al. 2005). Surprisingly, little 
evidence for a role of the X chromosome in complex diseases exists from GWAS. As of 2013, 
less than 50 associations exist on the X chromosome (Hindorff, MacArthur et al. 2013). While 
this may reflect a biological phenomenon (e.g. few mutations on chromosome X are risk variants 
for complex diseases and traits), a review of the literature suggests otherwise. Namely, 67% of 
GWAS during 2011 alone neglected to analyze chromosome X (Wise, Gyi et al. 2013). This 
itself was likely due to differences in statistical tests needed for chromosome X than the 
autosomes (non-sex chromosomes). Given this apparent gap in the field of GWAS and vast 
amount of unanalyzed data, we have developed a statistical package to carry out X-wide 
association analysis (XWAS) and further applied it to a number of autoimmune disorders 
(Chapter 3). 
 
In addition to cracking the case of missing heritability, the plain vanilla model of GWAS was 
also extended to explore the genetic overlap between phenotypes. As more GWAS were 
published, the overlapping associations between phenotypes became apparent, many of which 
supported known comorbidities and pleiotropies (Sirota, Schaub et al. 2009; Cotsapas, Voight et 
al. 2011; Sivakumaran, Agakov et al. 2011; Solovieff, Cotsapas et al. 2013). For example, type-1 
diabetes and rheumatoid arthritis, two diseases with known comorbidity (Somers, Thomas et al. 
2009), share 12 associations (Hindorff, MacArthur et al. 2013). Thus as increasing evidence 
came to light regarding the genetic overlap between phenotypes, many have extended GWAS to 
be carried out on more than one phenotype (Klei, Luca et al. 2008; Hartley, Monti et al. 2012; 
Andreassen, Thompson et al. 2013; Solovieff, Cotsapas et al. 2013; Andreassen, Harbo et al. 
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2014). Various methods exist –some aim to identify shared genetic loci, while others aim to 
identify the pairs or sets of diseases that share pathogenesis. Here, I have developed a principal 
component based method that elucidates sets of diseases sharing genetic pathogenesis and 
highlights pathways that may be enriched for genes underlying shared pathogenesis. I have 
further applied this method to a number of GWAS datasets spanning autoimmune, neurological, 
psychiatric and other disorders and traits (Chapter 4).  
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Chapter 2: Predicting signatures of “synthetic associations” and 
“natural associations” from empirical patterns of human genetic 
variation  
 
(Chang and Keinan 2012) 
2.1 Introduction 
Recent years have seen a plethora of Genome-wide association studies (GWAS) finding 
thousands of common markers that are associated with hundreds of diseases and other traits. 
GWAS were initially founded on the Common Disease-Common Variant hypothesis (Reich and 
Lander 2001; Pritchard and Cox 2002; Iles 2008), which predicted that common complex 
diseases are most likely caused by a few common variants. As a consequence, the design of most 
GWAS consisted of genotyping common tag single nucleotide polymorphisms (SNPs) and 
comparing their allele frequencies between cases and controls. Some limitations of this design 
have been the topic of much recent discussion, with the gap between association and causality 
and the relatively small portion of heritable variation explained by associated markers drawing 
the most concern (Maher 2008; Frazer, Murray et al. 2009; Manolio, Collins et al. 2009; Eichler, 
Flint et al. 2010). Several hypotheses aiming to explain the missing heritability have been 
proposed, including the roles of structural variants, gene-gene interactions, gene-environment 
interactions, epigenetics, and complex inheritance (Maher 2008; Frazer, Murray et al. 2009; 
Manolio, Collins et al. 2009; Eichler, Flint et al. 2010). In addition, rare variants of relatively 
high penetrance contributing to disease risk (Pritchard 2001; Bodmer and Bonilla 2008) has also 
been suggested as a source of missing heritability since rare variants have not been directly 
observed in most GWAS, and they might be differently tagged by common markers (McCarthy, 
Abecasis et al. 2008; Cirulli and Goldstein 2010; Wang, Dickson et al. 2010).  
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Given this renewed interest in such variants, an investigation into their effect on GWAS 
association signals is warranted. A recent simulation-based study showed that rare causal 
variants can often create “synthetic associations,” namely significant associations of common 
markers induced by the combined effect of one or more rare causal variants (Dickson, Wang et 
al. 2010). Dickson et al. further showed that a synthetically associated common marker could be 
substantially further away than expected had the underlying causal variant been common, and 
that synthetic associations are expected to be on average of lower minor allele frequency (MAF) 
than associations due to underlying common causal variants (Dickson, Wang et al. 2010). These 
predictions may partially explain why resequencing fine-mapping efforts, which are based on 
patterns of linkage disequilibrium (LD) of common variants, have often been unsuccessful in 
uncovering causal variants (McCarthy, Abecasis et al. 2008; McCarthy and Hirschhorn 2008; 
Dickson, Wang et al. 2010). While the development of new methods and study designs for 
associating rare causal variants is underway (Madsen and Browning 2009; Bansal, Libiger et al. 
2010; Cirulli and Goldstein 2010; Han and Pan 2010; Hoffmann, Marini et al. 2010; Longmate, 
Larson et al. 2010; Oksenberg and Baranzini 2010; Price, Kryukov et al. 2010; Rosenberg, 
Huang et al. 2010; Takeuchi, Kobayashi et al. 2011; Wu, Lee et al. 2011), the predictions of 
Dickson et al. are influencing analyses of such studies, as well as the interpretation of traditional, 
genotyping-based GWAS (e.g. (Fellay, Thompson et al. 2010; Shatunov, Mok et al. 2010)).  
 
A few instances of rare causal variants have already been well established (Cohen, Boerwinkle et 
al. 2006; Romeo, Pennacchio et al. 2007; Kathiresan, Willer et al. 2009), including the recently 
discovered, potentially rare causal variants in NOD2 that contribute to Crohn’s disease risk 
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(Hugot, Chamaillard et al. 2001; Ogura, Bonen et al. 2001; Bonen and Cho 2003; !The Wellcome 
Trust Case Control Consortium 2007). In this example, since an associated common marker in 
the same gene is in LD with at least two of the rare variants, it is possible that they contribute to 
the marker's association signal ( !The Wellcome Trust Case Control Consortium 2007), thus 
inducing a synthetic association. As only a few examples of rare causal variants contributing to 
complex disease are well established, the jury is still out on their prevalence and on how often 
they lead to synthetic associations, with several recent studies arguing that the phenomenon is 
not necessarily widespread (Orozco, Barrett et al. 2010; Anderson, Soranzo et al. 2011; Wray, 
Purcell et al. 2011). In light of this uncertainty, a detailed investigation of the signatures of 
synthetic associations and their implications is crucial for interpreting the results of genotyping-
based GWAS and for considering the alternative of association studies based on whole-genome 
or whole-exome sequencing. 
 
Two of the key questions with regards to “synthetic associations” are (1) what are the 
implications for the resequencing distance for fine-mapping of significant associations? and (2) 
how different is the MAF of synthetic associations from that of “natural associations” (i.e. 
associations where the underlying causal variants are common)? While these questions have 
been addressed in studies of simulated data (Dickson, Wang et al. 2010; Wray, Purcell et al. 
2011), those simulations did not account for the nature of disease loci and risk variants, nor did 
they account for the specific nature of human genetic variation. In the former, it has been shown 
that the effect size and frequency of the disease variants can alter the power of the test 
(Chapman, Cooper et al. 2003). While, in the latter, the mark left by human evolutionary history 
on patterns of genetic variation can greatly influence the nature of significant association signals, 
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which we address in the present study. For example, when considering samples from European 
populations, which have been the populations of choice of most GWAS, it is crucial to account 
for their recent explosive population growth that has led to an inflation in the proportion of rare 
variants and to an altered haplotype and LD structure, as well as to account for the well-
established effects of the earlier Out-of-Africa event on these genetic patterns (Tishkoff, 
Dietzsch et al. 1996; Dunning, Durocher et al. 2000; Reich, Cargill et al. 2001; Adams and 
Hudson 2004; Marth, Czabarka et al. 2004; Keinan, Mullikin et al. 2007; Keinan, Mullikin et al. 
2009; Keinan and Clark 2012).  
 
Here, we focus on the question of how empirical LD patterns can affect signals of “synthetic 
association” by investigating them in real human population genetic data. Through this, we aim 
to derive a better understanding of synthetic associations and their practical implications. Using 
empirical resequencing data, we randomly assume certain variants as increasing disease risk, 
determine cases and controls accordingly, and conduct an association study using genotyping 
data of the same individuals from arrays that have been employed in most GWAS. To illuminate 
and quantify signatures that are specific to “synthetic associations”, we repeat the process for 
rare and common causal variants and contrast the characteristics of synthetic associations with 
those of natural associations.  
 
We aim to elucidate how far associations are from the underlying causal variants, how their 
frequencies are distributed and, more importantly, how these different signatures alter the design 
of fine-mapping studies. To examine possible heterogeneity in these signatures across the 
genome and across populations with different evolutionary histories, we repeat the analysis for 
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several resequencing loci on different chromosomes and for two populations, one West African 
and one North European. The novelty of this study is in elucidating implications of synthetic 
associations and how they may affect fine-mapping strategies with the use of data that maintains 
LD patterns observed in human populations.   
 
2.2 Results  
 
To empirically investigate the signatures of “synthetic associations”, we needed to examine 
scenarios in human genetic data where the presumed disease risk variants—rare or common—are 
known. Thus, we considered “disease loci” in the ENCODE regions that were sequenced as part 
of HapMap 3 (Altshuler, Gibbs et al. 2010). The advantage of using these resequencing data is 
that we could observe variants of much lower allele frequency that are also free of ascertainment 
biases, which plague genotyping arrays (Clark, Hubisz et al. 2005; Frazer, Ballinger et al. 2007; 
Keinan, Mullikin et al. 2007; Albrechtsen, Nielsen et al. 2010). Equipped with resequencing data 
for over 110 individuals in each population, we studied variants that were of frequency as low as 
0.9% (after exclusion of singletons). We randomly assigned variants within each disease locus as 
being causal and considered individuals carrying any one of these variants to have elevated 
disease risk. We then probabilistically assigned individuals to be either cases or controls based 
on their assigned risk. To mimic the case of many rare variants of large effect size underlying 
synthetic associations, and to contrast it with that of a few common variants of moderately low 
effect sizes underlying natural associations, we investigated three scenarios: (i) 2 common causal 
variants with a genotypic relative risk (GRR) of 1.5, (ii) 5 and (iii) 9 rare causal variants with a 
genotypic relative risk of 3. We verified that our results are not an artifact of the number of 
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causal variants, as illustrated in the following, by comparing with a less realistic scenario of 5 
common causal variants. We also considered a random assignment of cases and controls, which 
provides a null distribution in the absence of any risk alleles. 
 
After obtaining a set of cases and a set of controls, we performed an association study using the 
genotyping array data for the same individuals from HapMap 3 (Altshuler, Gibbs et al. 2010), 
without considering any of the resequencing data in which disease loci have been emulated 
(Materials and Methods). This mimics the conditions and variant-type of actual genotyping-
based GWAS, which typically utilize array data of mainly common markers, most often using 
the same or similar arrays to those we have used for our analyses (Affymetrix Human SNP array 
6.0 and Illumina Human1M). We report results for association testing of all genotyped markers 
located within 3 cM of the resequenced disease locus, after verifying that the vast majority of 
significant associations are within those bounds (Materials and Methods). Similar to the 
requirement of genome-wide significance in a GWAS, we required significance following 
multiple-hypothesis correction for the entire region tested, such that our results can be 
extrapolated to genome-wide studies. We repeated the association testing for 5 different disease 
loci (Table 2.1) and for 50 sets of random assignments of causal variants in each locus. For each 
of these sets, we repeated the association testing in 10 replicates, varying between them only the 
stochastic assignment of cases and controls, for a total of 500 association tests in each locus for 
each of the three scenarios of causal variants. We also considered separately both a European 
(CEU) and a West African (YRI) population. Because of the relatively small sample size of ~110 
individuals, we simulated a larger sample using HAPGEN (Spencer, Su et al. 2009), which 
maintains the genetic variation observed in the original data, including patterns of LD and MAF 
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(Materials and Methods).  
 
All scenarios show significant associations much more often than the false discovery rate of 5% 
(Table 2.S1). To determine whether “synthetic associations” due to underlying rare variants tend 
to be further away than “natural associations” due to underlying common variants, we considered 
for each association test the distance between any association and the causal variant with which 
it is in strongest LD (Materials and Methods). We found that the median distance, over the many 
hundreds of associations found across the 500 tests, is variable across the five loci and—to some 
extent—between the two populations (Figure 2.1). Synthetic associations tend to be much further 
than natural associations, as previously predicted (Dickson, Wang et al. 2010), though for one 
region (disease locus #1) both synthetic and natural associations are in close proximity to the 
causal variants (Figure 2.1). Alternatively, when considering the distance between an association 
and the closest causal variant (rather than the one in strongest LD), the distance of synthetic 
associations is reduced, yet generally remains greater than that of natural associations (Figure 
2.S1). Taken together, these results lead us to ask what factors contribute to this increased 
distance, and, more importantly, does this increased distance impact the choice of fine-mapping 
strategies?   
 
We explored several plausible explanations for this increased distance. Firstly, we ensured that 
the increased distance of rare causal variants is not due to more variants in those scenarios (5 and 
9) than in the scenario of common causal variants (2) by repeating our analysis for cases with 5 
common causal variants. We observed no increase in association distance of resultant natural 
associations (Figure 2.S2), revealing that the increased distance is not due to the increased 
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number of causal variants. Secondly, we investigated the hypothesis that increased marker effect 
size can cause greater association distances as effect size, in addition to the correlation between 
the causal variant and the marker, is proportional to the power of an association test (Chapman, 
Cooper et al. 2003). We investigated this hypothesis by increasing the effect size of common 
causal variants to equal that in the scenario of rare causal variants, though such an effect size 
might be considered unrealistic for common variants. The median association distance of the 
resulting natural associations indeed increases for all regions and populations, but is still 
considerably lower than synthetic associations in most cases (Figure 2.1).  
 
We next tested whether the age of the mutation played a role in increasing association distances 
for synthetic associations. As rare variants are, on average, resultant of more recent mutations 
compared to common variants, recombination would have had less time to operate, thus resulting 
in diminished decay of LD and haplotype structure around rare variants. To test whether the age 
of the mutation plays a part in explaining our results, we partitioned rare causal variants in two 
age groups: i) variants due to relatively more recent mutations and ii) variants due to relatively 
older mutations. Variants with minor alleles present in only a single population fell into the 
former category, while those with minor alleles present in more than one population fell into the 
latter (Materials and Methods). We observed a larger distance between an associated marker and 
the causal variant with which it is in highest LD for more recent mutations than for older 
mutations (Figure 2.2). Out of the 4 disease loci for which enough data was available to perform 
this analysis, 3 in YRI and 2 in CEU exhibit a median distance from older rare causal variants 
that is at least 41% less than the median distance from more recent causal variants. Combined, 
these results suggest that the increased distance of synthetic associations compared to natural 
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associations is partially due to the young age of the mutations that give rise to rare risk alleles, as 
well as due to the higher effect size that is likely to be implicated for rare risk alleles.  
  
The main concern regarding synthetic associations is how its signatures alter the search for the 
actual causal variant(s). Specifically, how far should one sequence around an association in order 
to capture causal variants? We addressed this question using two approaches. We first computed 
for each scenario of causal variants the fraction of tests (out of all tests with any significant 
association) that had at least one associated marker within any given distance of the causal 
variant with which it is in highest LD (Materials and Method). We found that for common causal 
variants, a shorter resequencing distance of 0.01 cM is enough to capture a causal variant in 90% 
of the tests in CEU and 77% for YRI (Figure 2.3). For rare causal variants, combined over all 
disease loci, at least 90% of tests discovered an association within 0.1 cM of a causal variant 
(Figure 2.3). Secondly, we investigated a scenario in which fine-mapping consists of sequencing 
the LD block of associations as observed in the data. Hence, we estimated the probability that an 
associated marker is in the same LD block as any of the causal variants, with the definition of 
LD blocks being based only on markers from the genotyping arrays, which are relatively 
common (Materials and Method). On average, the LD blocks spanned 0.007 cM for CEU and 
0.005 cM for YRI, including the addition of a flanking region of 0.0005 cM to be inclusive. We 
found that in CEU, 94% of associated markers were in the same LD block as a common causal 
variant, while the same was true for only 78% of associated markers in the rare causal variant 
case. A similar trend was observed for YRI, albeit less marked, where 79% of natural 
associations captured a causal variant, but only 73% of synthetic associations captured a causal 
variant.  
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Finally, we explored the minor allele frequency (MAF) of associated markers. Summing over all 
disease loci and populations, <1% of natural associations had MAF below 0.1, while this 
proportion increased to 15-28% for synthetic associations (Figure 2.4). Dissecting the signal 
further by region and population, we found that while some regions display less than 2.4% 
difference between the median MAF of natural associations and synthetic associations (disease 
locus #1 in YRI, #2 in CEU), others display an almost 200% difference (#4 in CEU). Synthetic 
associations also display a larger standard deviation in associated MAF as compared to natural 
associations, with all but one region displaying a difference ranging from 17%- 70% (Table 2.2).  
 
2.3 Discussion 
 
With the use of HapMap 3 resequencing and genotyping data from five different genomic 
regions and two populations (Altshuler, Gibbs et al. 2010), we considered several scenarios of 
disease risk loci, and performed association tests to investigate the signatures of synthetic 
associations and how they alter one’s approach for studying them. We found that the median 
distance of synthetic associations, while greater than that of natural associations, still never 
exceeds 0.15 cM (~150 kb) for any of the 10 locus-by-population settings. Even if we instead 
consider the worst-case scenario of the largest distance between any association and any causal 
variant, its median still never exceeds 0.41 cM (~410 kb). These results are in clear contrast to 
the results of a previous simulation-based study that showed the median of the largest distance to 
be 5 cM (5 Mb) (Dickson, Wang et al. 2010). The difference between the two studies may be 
attributed to differences in the frequencies of rare causal variants. We considered rare alleles of 
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frequency in the range 0.005-0.04 (average across all variants of 0.019), while Dickson et al. 
simulated allele frequencies in the range 0.005-0.02 (Dickson, Wang et al. 2010) (average of 
0.0125 assuming uniform sampling). However, when we restricted to a narrower range of 
frequencies up to 0.02 (average of 0.012), we still observed no locus for which the median 
distance of synthetic association exceeds 0.5cM (‘All variants’ in Figure 2.2). It is unlikely that 
any remaining slight difference in risk allele frequency would result in over an order of 
magnitude difference in association distance.  
 
A more substantial difference between the two studies lies in the data analyzed. Dickson et al. 
conducted simulations of constant effective population size, uniform recombination rate, and 
purely neutral disease loci, with association testing based on a simulated “genotyping array” that 
follows a uniform ascertainment bias (Dickson, Wang et al. 2010). Here, we have analyzed data 
with empirically observed LD patterns, and have based association testing on data from real 
genotyping arrays as designed for GWAS. Put together, while theory posits that a median 
distance of synthetic associations of 5cM is possible, characteristics of empirical data suggests 
that such cases will not be common, and that even under the worst-case scenario the vast 
majority of synthetic associations are at least an order of magnitude closer.  
 
By considering which of the rare polymorphisms are population-specific, and hence likely to be 
more recent, we illustrated that the increase in association distance can partially be due to the age 
of the mutation. This is likely a result of recombination having had less time to break down the 
haplotype surrounding more recent mutations. We also considered common causal variants with 
a higher effect size and showed that an increased effect size can lead to an increased association 
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distance. As rare causal variants contributing to an association signal are likely to have higher 
effect sizes than common causal variants, the increased distance for synthetic associations can 
thus partially be due to the larger effect size. Our findings thus suggest that synthetic associations 
do not necessarily entail further causal variants. While these explanations apply in scenarios 
where single causal variants contribute to an association signal, the increased distance for 
synthetic associations can also result from the contribution of multiple causal variants to a single 
signal of association, thus exceeding the expectations of distance given two variants in LD. 
 
To assess the impact of this increased association distance, we explored the probability that an 
association test had at least one association where the causal variant with which it was in highest 
LD lay within a given distance from the association. We found that for rare causal variants a 
window size of 0.1 cM was sufficient to capture at least one causal variant in such a manner in at 
least 90% of the tests for all regions and populations (Figure 2.3). Alternatively, by following an 
LD block based approach for fine-mapping, 73-79% of associations capture at least one of the 
rare causal variants within the same LD block. This suggests that traditional LD block-based 
fine-mapping also offers a surprisingly high probability of discovering some of the causal 
variants, though there could still be added benefit from sequencing a larger region. Thus, given a 
resequenced region, one is almost as likely to capture a rare causal variant as one is to capture a 
common causal variant. Preliminary analysis suggests that it is difficult to predict the optimal 
region to resequence given a specific disease locus, as no single factor such (i.e. pair-wise LD 
decay) can sufficiently predict this distance (data not shown). Further work is thus necessary in 
order to determine which factors that influence synthetic associations, such as the age of 
mutation, causal variant effect size, haplotype structure and the stochastic coupling of multiple 
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rare variants on the background of a common marker, play a role in a given association signal. 
 
In a further analysis, we found that rare causal variants underlying synthetic associations entail 
that the associated markers will themselves be of lower frequency compared with natural 
associations (Figure 2.4), a result consistent with previous simulation studies (Dickson, Wang et 
al. 2010; Wray, Purcell et al. 2011). When narrowing the number of associations to only the most 
significant, we found that this further reduced the allele frequency of synthetic associations 
(Figure 2.S3). In addition, we found that the frequency of synthetic associations often had a 
larger standard deviation than natural associations (Table 2.2). These results have two 
implications. Firstly, it suggests that synthetic associations as compared to natural associations 
are likely to have underestimated effect sizes of the causal variant due to reduced associated 
allele frequencies (Spencer, Hechter et al. 2011) (especially when analyzing the most significant 
association) and from incomplete LD with the causal variant. Secondly, this suggests that the 
standard deviation of the associated minor allele frequency can offer a way to flag for underlying 
rare causal variants that induce potential synthetic associations; given a larger standard deviation 
of associated frequencies, it would be advised to follow a fine-mapping study design for 
synthetic associations.  
 
With the >1000-fold human population growth in the last hundreds of generations, the amount of 
rare variation is much greater than expected (Coventry, Bull-Otterson et al. 2010; Keinan and 
Clark 2012). This explosive addition of rare variation entails an LD structure that is yet to be 
quantified, but certainly disparate than the LD structure of common variants that have been 
extensively studied. In addition, the earlier founder events as modern humans migrated out of 
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Africa and settled across the globe have been shown to greatly alter patterns of genetic variation 
(Tishkoff, Dietzsch et al. 1996; Dunning, Durocher et al. 2000; Reich, Cargill et al. 2001; 
Ramachandran, Deshpande et al. 2005; Keinan, Mullikin et al. 2007). For this reason we studied 
both a West African population and a population of European ancestry, with differences between 
the two reinforcing the importance of taking demographic history into consideration by studying 
empirical data. Signatures of synthetic and natural associations are shaped by demographic 
history, as well as by different selective pressures. This assertion is supported by the highly 
variable behavior—across genomic regions and across the two populations—of all the signatures 
we observed.  
 
In conclusion, this study delivered a characterization of several signatures of synthetic 
associations and assessed their impact on the search for the causal variant(s) underlying the 
signal. While our study does not participate in the debate on how frequently synthetic 
associations occur, it is relevant in any situation they do. In this study, we illustrated that because 
synthetic associations are likely to be more distant from causal variants, fine-mapping studies 
should look further than when searching for common causal variants, but to a much lesser extent 
than previously suggested. We also propose the larger standard deviation of associated allele 
frequencies as a way to detect potential rare causal variants at play. Additional analysis is 
warranted though, to elucidate the quantitative relationship between genetic architecture, 
demographic history, allele frequency and association signals. Finally, although the debate 
remains open as to the contribution of rare risk alleles to human complex diseases and to the 
ensuing abundance of synthetic associations (Orozco, Barrett et al. 2010; Anderson, Soranzo et 
al. 2011; Goldstein 2011; Wray, Purcell et al. 2011), our results offer new guiding principles for 
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determining a length of a region to fine map, and for considering the alternative of an association 
study based on whole-genome sequencing. 
 
2.4 Materials and Methods  
2.4.1 Data 
We obtained from HapMap 3 (Altshuler, Gibbs et al. 2010) genotyping array data for YRI 
(Yoruba in Ibadan, Nigeria) and CEU (individuals in Utah with Northern and Western European 
ancestry from the Centre d’Etude du Polymorphisme Humain collection) and resequencing data 
of five ENCODE regions, each 100kb in length (Table 2.1), for 115 YRI and 111 CEU 
individuals. We also obtained resequencing data for 60 TSI (Toscani in Italia) samples and 60 
LWK (Luhya in Webuye, Kenya), which we used for the variant age analysis (below). We 
considered each resequencing region as a disease locus from which to select causal variants. 
Using resequencing data facilitates higher concentration of rare variants and is free of the 
ascertainment biases associated with genotyping arrays (Clark, Hubisz et al. 2005; Frazer, 
Ballinger et al. 2007; Keinan, Mullikin et al. 2007; Albrechtsen, Nielsen et al. 2010).  
 
2.4.2 Simulated Data 
 
Due to the low sample size, we employed HAPGEN (Spencer, Su et al. 2009) to simulate 10,000 
individuals for each population –a strategy previously employed to investigate the estimation of 
relative risks (Spencer, Hechter et al. 2011). HAPGEN simulates additional haplotypes by 
treating each new haplotype as a mosaic of already present haplotypes. We refer readers to 
(Spencer, Su et al. 2009) for additional details on HAPGEN.  
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We first phased and imputed missing data with BEAGLE v3.3 (Browning and Browning 2007). 
We then simulated additional data for each resequencing region and the 3 cM-flanking window 
for each region using HAPGEN with a recombination map from the March 2006 human 
reference sequence (NCBI Build 36, hg18) and a null mutation rate as input parameters. We 
ensured that the LD patterns of the original data (for rare and common variants) were maintained 
(Figure 2.S4). We also ensured that allele frequencies in the simulated data do not change 
drastically from the original data as no variants were observed that were initially of very low 
frequency and attained a much higher frequency and vice versa in the simulated dataset (Figure 
2.S5-2.S6).  
 
Association tests were performed using the simulated data from the HapMap 3 genotyping array 
data, excluding any causal variants that happen to be in the genotyping array data. We report 
results for an association study for SNPs located in the disease locus and in flanking regions of 3 
cM on each side (from which no causal variants are chosen), as almost no associations were 
observed to fall beyond that distance (data not shown). In our study, rare causal variants have 
risk allele frequencies in the simulated data between 0.005 and 0.04 (we note that a portion of 
this range is defined as “low frequency”, rather than rare, by some studies), and common causal 
variants have risk allele frequencies in the simulated data between 0.1 and 0.3. In testing for 
association, we considered all SNPs of all allele frequencies from the genotyping data. All 
coordinates and genetic distances in this paper are according to the March 2006 human reference 
sequence (NCBI Build 36, hg18). 
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2.4.3 Disease model & association study design 
 
We considered each individual as a case or a control with a probability proportional to the 
individual’s assigned risk, which is elevated if the individual has one or more risk alleles. We set 
the baseline risk as 0.15 and the genotypic relative risk to 1.5 for the scenario of common causal 
variants. We also explored an unrealistic genotypic relative risk of 3 for common causal variants 
to investigate the influence of effect size on association distance. For rare causal variants, we 
assigned a higher genotypic relative risk of 3. While the use of a fixed GRR for variants of 
differing allele frequencies results in differing portions of variance explained by each variant, it 
is a more realistic disease model. By fixing variance explained, rarer variants would tend to have 
higher, and perhaps somewhat unrealistic, GRRs. Because we have fixed GRR and allowed the 
proportion of variance explained to vary, an association test will have more power in detecting 
variants of higher allele frequency given a fixed GRR. 
 
For the common causal variants scenario, we randomly assigned 2 SNPs from the resequencing 
data as causal, while we assigned either 5 or 9 for the rare causal variants scenario. To ensure 
that the number of causal variants did not affect our results, we also studied a scenario with 5 
common causal variants in loci where this was feasible. For each scenario of a certain type and 
number of causal variants, 50 sets of causal variants were randomly selected, with replacement 
between groups. Each of these 50 sets allows for a possibly different risk for each individual. For 
each of these 50 sets, we repeated 10 replicates of randomly assigning cases and controls 
according to the same individual assigned risk.  
 
In each of the 500 association tests (50 different variant groups and their 10 phenotypic 
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replicates), we randomly chose 1000 cases and 1000 controls according to the individual’s 
assigned risk. This ensures that the same number of cases and controls were shared across all 
analyses, thereby having comparable statistical power. For each scenario of type and number of 
causal variants, we pooled together the results from these 500 tests for the statistics and figures 
presented in this study. Similarly, we generated 500 tests for each disease locus with randomly 
assigned case/control status to serve as a control. 
 
All association tests were done with PLINK's logistic regression function (Purcell, Neale et al. 
2007). Significance thresholds were determined with a region-wide Bonferroni correction. For 
the control scenario of random assignment of cases and controls, 2.12% of the association tests 
showed a significant association as compared with the expectation of 5%. 
 
2.4.4 Distance analysis 
 
We determined genetic distances based on the Oxford genetic map based on HapMap2 data 
(Myers, Bottolo et al. 2005; Frazer, Ballinger et al. 2007). For SNPs missing from HapMap2, we 
estimated the position as the linear interpolation of the genetic positions of the two closest SNPs. 
The association distances were determined by computing the genetic distance between an 
associated SNP and the causal variant with which it was in highest LD, measured in r2. Pairwise 
r2 values were calculated in pLINK (Purcell, Neale et al. 2007). 
 
2.4.5 Age of mutation analysis 
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To partition rare variants based on the age of the mutation, we first narrowed the range of the 
risk allele frequency in the simulated data to 0.005 and 0.02 in order to ensure a roughly equal 
partition into the two age groups. We discarded disease locus #1 from this analysis because it 
had too few rare variants to allow their portioning into two groups (Table 2.1). Rare variants in 
the 111 CEU individuals were defined to be relatively more recent if only the major allele was 
observed in the resequencing of 115 YRI individuals and 60 TSI individuals in the original data; 
the variant was defined as relatively older otherwise. We repeated the above analyses for each of 
these groups separately, such that in each association testing either all causal variants are older or 
all are more recent. We repeated the same analysis in YRI with CEU and 60 LWK as out groups. 
We duly note that polymorphisms absent from the limited number of samples may not be 
monomorphic in the population as a whole, hence not all mutations leading to relatively older 
variants precede those leading to variants in the relatively more recent class. Yet, this represents 
only a small fraction of variants and variants in the relatively older class are expected to be older 
on average than those belonging to the more recent class. It is also important to note that false 
positive variant calls are added to the more recent group despite the erroneous call. This scenario 
is highly unlikely in our analyses due to the stringent quality control measures taken in HapMap 
3 [45] and the exclusion of singletons in our study. For each of these two scenarios of causal 
variants, we similarly chose 50 sets of causal variant groups with 10 phenotypic replicates each 
and obtained maximal distances as above. For comparison, we repeated the analysis for random 
rare causal variants in the narrowed range of frequency of 0.005-0.02 used here, irrespective of 
mutation age. 
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2.4.6 Resequencing distance analysis 
 
For each association test we explored whether a causal variant with which an association is in 
highest LD (measured in r2) is within a given genetic distance from the association. For each 
simulated scenario and resequencing window size ranging from 0 cM to 10 cM, we calculated 
the proportion of tests that have at least one such association.  
 
For the second analysis, we observed over all significant associations if any causal variant was in 
the same LD block as an association. LD blocks were estimated in pLINK with the genotyping 
data (Purcell, Neale et al. 2007) and 0.0005 cM was added to the start and end coordinates in 
order to compensate for the uncertainty in these estimates.  
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2.5  Figures 
 
 
Figure 2.1. Distance of synthetic and natural associations from the causal variant it is in 
greatest LD with.  
Box plot of the distance between any associated SNP and causal variant it is in highest LD with, 
measured in r2, for (a) YRI and (b) CEU in four scenarios: 2 common causal variants with a 
GRR of 1.5 (dark blue), 2 common causal variants with an unrealistic GRR of 3 (light blue), 5 
and 9 rare causal variants with a GRR of 3 (red and gold respectively). Distances vary greatly 
between the different disease loci (x-axis) as well as between populations, but in all regions the 
median (line within each box) is larger for rare causal variants than for common causal variants 
of lower effect size. Increasing the effect size can result in higher association distance as is 
observed most notably in region #5.  
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Figure 2.2: Distance of causal variant from “synthetic associations” partitioned by the age 
of the mutation.  
Box plot similar to Figure 2.1, while separating rare variants in CEU and YRI into a more recent 
and an older class (Materials and Methods). Variants due to more recent mutations result in 
much increased distance between the associated SNP and the causal variant with highest LD in 3 
regions in YRI and 2 regions in CEU. Results are presented for only 4 of the disease loci due to 
lack of relevant data in locus #1. Note that the risk allele frequency range for rare variants is 
narrower compared to Figure 2.2 (Materials and Methods) and that the y-axis scale is different 
between the two populations.  
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Figure 2.3: Resequence window size necessary to capture at least one causal variant.  
The figure presents for a given window size, the fraction of tests combined over all regions with 
significant associations where at least one association is within the given distance from the 
causal variant it is in highest LD with. The colors correspond to the same scenarios as in Figure 
2.1. Resequencing need not extend much further than in the common causal variant case, as a 
window of size of 0.1 cM has at least one association tagging a rare causal variant in >90% of 
the tests between both populations and all regions.  
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Figure 2.4. Minor allele frequency of associated variants.  
Box plot of the minor allele frequency for all associated variants in the different scenarios. 
Although synthetic associations have median MAF lower than that of natural associations, the 
range of MAF for synthetic associations varies across the different loci and populations. The 
median MAF is similar between the natural and synthetic associations for a few loci (disease 
locus #2 in CEU and #1 in YRI).  
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Figure 2.S1: Distance between association and closest causal variant.  
The figure mirrors Figure 2.1, but plots instead the distance between an association and the 
closest causal variant. The distance of synthetic associations is reduced, yet generally remains 
greater than that of natural associations. 
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Figure 2.S2: Distance of common causal variant is not sensitive to the number of causal  
variants.  
The figure mirrors Figure 2.1, but to the inclusion of results for 5 common causal variants 
(“Common (5)”) in loci where this was feasible (all for CEU). All other results are reproduced 
from Figure 2.1. The difference in distance between common and rare causal variants remains 
even with 5 common causal variants.  
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Figure 2.S3: Minor allele frequency of most significant association.  
The figure mirrors Figure 2.4, but displays the minor allele frequency of only the most 
significant association across each test. The median frequency of the most significant association 
is reduced for synthetic associations. 
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Figure 2.S4: Empirical LD patterns are preserved in HAPGEN simulations.  
Plotted above is data for region 1 in CEU. For each 0.01 cM bin, the figure presents the mean 
pair-wise LD (measured in r2) between variants from the resequencing and genotyping data for a) 
common markers (minor allele frequency > 0.04) or b) common and rare markers (minor allele 
frequency < 0.04). We observe that HapMap 3 LD patterns (blue) are largely preserved in 
HAPGEN simulations (green). Missing points reflect lack of data for certain distance bins. 
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Figure 2.S5: Minor allele frequency in HapMap3 compared to minor allele frequency in 
HAPGEN simulations.  
Plotted are minor allele frequencies in HapMap 3 (x-axis) compared to minor allele frequencies 
in HAPGEN simulations (y-axis) for a) YRI and b) CEU. Each row represents a separate region. 
No drastic departures from the original minor allele frequencies are observed in the simulated 
data.   
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Figure 2.S6: Minor allele frequency in HapMap3 compared to minor allele frequency in 
HAPGEN simulations for frequencies below 0.08.  
Same plot as in Figure 2.S5 showing only variants with frequencies below 0.08. As in Figure 
2.S5, no drastic departures from the original minor allele frequencies are observed in the 
simulated data 
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2.6. Tables 
 
Table 2.1: List of ENCODE regions used as disease loci [45]. 
Locus # 
ENCODE 
 name Chromosome Location (bp) 
# Common  
variants*  
(YRI/CEU) 
# Rare  
variants* 
(YRI/CEU) 
1 ENr221 5 
56071684 
-56170943 57/36 59/20 
2 ENm010 7 
27124056 
-27223436 58/40 117/57 
3 ENr321 8 
119082399 
-119182123 72/20 108/45 
4 ENr123 12 
38827200 
-38925373 43/62 72/50 
5 ENr213 18 
23920590 
-24019175 60/54 108/41 
*Variants with MAF of either between 0.1 - 0.3 or between 0.005 – 0.04 after resampling of haplotypes using 
HAPGEN.   
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Table 2.2: Standard deviation of minor allele frequency for associated variants. 
Locus # Common (2) Rare (5) Rare (9) 
YRI    
1 0.086 0.134 0.131 
2 0.117 0.154 0.150 
3 0.114 0.131 0.124 
4 0.124 0.151 0.145 
5 0.113 0.121 0.126 
CEU    
1 0.084 0.113 0.116 
2 0.056 0.118 0.121 
3 0.064 0.152 0.143 
4 0.121 0.121 0.126 
5 0.073 0.133 0.136 
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Table 2.S1: Percentage of tests with significant associations.  
 
  YRI 
Locus # 
Common 
(2,1.5)^ Common(2,3)^ Rare (5)^  Rare (9)^ Random* 
1 31.4 100 93.8 97.2 2 
2 19.8 99.8 98 97.6 2.8 
3 38 100 95.8 99.6 3.2 
4 31.8 99.8 86.4 94.4 2 
5 28.6 100 94 97.2 1.8 
Mean 29.92 99.92 93.6 97.2 2.36 
CEU 
Locus # 
Common 
(2,1.5)^ Common(2,3)^ Rare (5)^  Rare (9)^ Random* 
1 67.6 100 91.6 95.6 2.2 
2 58 100 95 99.6 2.4 
3 37.6 100 80 84.6 1.2 
4 54.2 100 89.6 96.8 2.2 
5 36 100 87.6 97 1.4 
Mean 50.68 100 88.76 94.72 1.88 
 
 
^ Corresponds to the notation of Figure 2.1.  
*  Corresponds to random phenotypic assignment.  
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Chapter 3: Accounting for eXentricities: Analysis of the X chromosome in 
GWAS reveals X-linked genes implicated in autoimmune diseases 
 
(Chang, Gao et al. 2014) 
3.1 Introduction 
Over the past decade, genome-wide association studies (GWAS) have contributed to our 
understanding of the genetic basis of complex human disease. The role of the X chromosome (X) 
in such diseases remains largely unknown because the vast majority of GWAS have omitted or 
incorrectly analyzed X-linked data (Wise, Gyi et al. 2013). As a consequence, though X 
constitutes 5% of the nuclear genome and underlies almost 10% of Mendelian disorders 
(Hamosh, Scott et al. 2002; Hamosh, Scott et al. 2005; Amberger, Bocchini et al. 2009; 
Amberger, Bocchini et al. 2011), it harbors only 15 out of the 2,800 (0.5%) total significant 
associations for nearly 300 traits (Green and Guyer 2011; Hindorff, MacArthur et al. 2013; Wise, 
Gyi et al. 2013). Even this 0.5% of associations contains a higher proportion of false positives 
than autosomal associations, as indicated by the occurrence of fewer X-linked than autosomal 
associations in putatively functional loci (<40%) (Hindorff, Sethupathy et al. 2009; Green and 
Guyer 2011). This phenomenon is likely due to the application of tools designed for the 
autosomes to X. We hypothesize that X explains a portion of “missing heritability” (Maher 2008; 
Manolio, Collins et al. 2009), especially for the many complex human diseases that exhibit 
gender disparity in risk, age of onset, or symptoms. This hypothesis is motivated by the 
importance of X in sexually dimorphic traits in both model organisms and human Mendelian 
disorders. The complex human diseases most extensively studied in GWAS are highly sexually 
dimorphic, including autoimmune diseases (Schuurs and Verheul 1990; Beeson 1994; Chataway, 
Feakes et al. 1998; Whitacre, Reingold et al. 1999; Bellamy, Beyers et al. 2000; Whitacre 2001; 
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Lockshin 2006; Fish 2008; Sawalha, Webb et al. 2008; Shen, Fu et al. 2010; Selmi, Brunetta et 
al. 2012), neurological and psychiatric disorders (Harper 1984; Gater, Tansella et al. 1998; 
Andersen, Launer et al. 1999; Lai, Kammann et al. 1999; Goldstein, Seidman et al. 2001; 
Aleman, Kahn et al. 2003; Wooten, Currie et al. 2004; Pike, Carroll et al. 2009; Jazin and Cahill 
2010; Baron-Cohen, Lombardo et al. 2011), cardiovascular disease (Lerner and Kannel 1986; 
Anderson, Odell et al. 1991; Mendelsohn and Karas 2005; Choi and McLaughlin 2007; 
Teslovich, Musunuru et al. 2010), and cancer (Muscat, Richie et al. 1996; Zang and Wynder 
1996; Matanoski, Tao et al. 2006; Naugler, Sakurai et al. 2007). Several mechanisms underlying 
sexual dimorphism have been suggested (Nelson and Ostensen 1997; Confavreux, Hutchinson et 
al. 1998; Whitacre 2001; Ellegren and Parsch 2007; Patsopoulos, Tatsioni et al. 2007; Fish 2008; 
Ober, Loisel et al. 2008), including the contribution of the X chromosome (Carrel and Willard 
2005; Ropers and Hamel 2005; Ross, Grafham et al. 2005; Ober, Loisel et al. 2008; Tarpey, 
Smith et al. 2009).  Variants on chromosome X may also be more likely to show sexually 
dimorphic traits as compared to the autosomes. Moreover, characterizing the role of X in 
complex diseases can provide insight into etiological differences between males and females, as 
well as a unique biological perspective on disease etiology because X carries a set of genes with 
unique functions (Saifi and Chandra 1999; Kemkemer, Kohn et al. 2009).  
 
X-specific problems that should be taken into consideration include, but are not limited to: 1) 
correlation between X-linked genotype calling error rate and the sex composition of a plate, 
which can lead to plate effects that correlate with sex and, hence, with any sexually dimorphic 
trait; 2) X-linked variants being more likely to exhibit different effects between males and 
females (Dobyns, Filauro et al. 2004), suggesting enhanced power of sex-stratified statistical 
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tests; 3) power of the analyses being affected by the smaller allelic sample size, the reduced 
diversity on X and other unique population genetic patterns (Keinan, Mullikin et al. 2007; 
Hammer, Mendez et al. 2008; Keinan, Mullikin et al. 2009; Hammer, Woerner et al. 2010; 
Keinan and Reich 2010; Lohmueller, Degenhardt et al. 2010; Gottipati, Arbiza et al. 2011); 4) 
quality control (QC) criteria that account for sex information to prevent filtering the entirety or a 
large fraction of the chromosome (Wise, Gyi et al. 2013); 5) sex-specific population structure 
leading to differential effects of population stratification (which could inflate the type I error rate 
(Patterson, Price et al. 2006; Price, Patterson et al. 2006; Novembre, Johnson et al. 2008)) 
between X and the autosomes; and 6) application of association tests designed for the autosomes, 
which leads to statistical inaccuracy.  
 
In this study, we take into account several of the above problems and apply X-aware strategies to 
investigate the role of X in complex diseases. Recent advancements of association test statistics 
for X have been made (Purcell, Neale et al. 2007; Zheng, Joo et al. 2007; Clayton 2008; Clayton 
2009; Thornton, Zhang et al. 2012; Tukiainen, Pirinen et al. 2014), with one study discovering 
new loci associated to height and fasting insulin (Tukiainen, Pirinen et al. 2014). These 
improvements account for some of the aforementioned problems, but are not extensively applied, 
and have never been applied in the context of gene-based tests of association. Here, we 
demonstrate that unutilized X data from hundreds of studies can be re-analyzed to uncover X-
linked disease etiology. We introduce methods and software for carrying out XWAS, which 
include X-specific QC, imputation, association methods, tests of sex-specific effects, and gene-
based tests (Materials and Methods). Though variants displaying dominance are readily exposed 
in males, overall hemizygosity in males reduces the effective sample size for X. We thus 
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increase statistical power by focusing on whole genes as functional units and combining tests of 
individual SNPs into gene-based tests (Neale and Sham 2004; Jorgenson and Witte 2006; 
Beyene, Tritchler et al. 2009; Liu, McRae et al. 2010; Li, Gui et al. 2011). This approach also 
surmounts issues of replication across studies with different sets of SNPs that arise from 
differing genotyping arrays and quality control filtering (Neale and Sham 2004; Beyene, 
Tritchler et al. 2009).  
 
A promising case study for investigating the role of X in disease risk involves autoimmune 
diseases (AID) and other diseases with a potential autoimmune component. Most AID are 
sexually dimorphic with many diseases more prevalent in one sex than the other (most in 
females) (Whitacre, Reingold et al. 1999; Whitacre 2001; Lockshin 2006; Gleicher and Barad 
2007).  Furthermore, they often show sex-specific symptoms, age of onset, and progression 
(Schuurs and Verheul 1990; Beeson 1994; Chataway, Feakes et al. 1998; Whitacre, Reingold et 
al. 1999; Bellamy, Beyers et al. 2000; Whitacre 2001; Lockshin 2006; Fish 2008; Sawalha, 
Webb et al. 2008; Shen, Fu et al. 2010; Selmi, Brunetta et al. 2012). While pregnancy (Nelson 
and Ostensen 1997; Confavreux, Hutchinson et al. 1998; Whitacre 2001) and other 
environmental factors (Tiniakou, Costenbader et al. 2013), as well as sex hormones (Nelson and 
Ostensen 1997; Confavreux, Hutchinson et al. 1998; Whitacre 2001; Fish 2008),  can contribute 
to sexually dimorphic characteristics, a role for X-linked genes has also been suggested (Ober, 
Loisel et al. 2008; Libert, Dejager et al. 2010; Bianchi, Lleo et al. 2011; Quintero, Amador-
Patarroyo et al. 2012; Selmi, Brunetta et al. 2012), with many having immune-related functions. 
Though AID have been extensively studied by GWAS, the majority of previously discovered 
loci have a small effect size and the combined effect of all associated loci only explains a 
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fraction of heritable variation in disease susceptibility (Tysk, Lindberg et al. 1988; Sofaer 1993; 
Jostins, Ripke et al. 2012). Despite the dozens of GWAS in AID, few have studied the 
contribution of X and, to date, little evidence of its role in AD has been provided (Green and 
Guyer 2011; Hindorff, MacArthur et al. 2013; Wise, Gyi et al. 2013), though X-linked loci 
overall may contribute to the heritability for some complex diseases (Yang, Manolio et al. 2011). 
Hence, we applied the X-specific analytical methods and software developed as part of this study 
to conduct an extensive XWAS of a number of AID and other diseases with a potential 
autoimmune component (DPACs) (Pagani, Gonzalez et al. 2011; Itariu and Stulnig 2014), for a 
total of 16 different datasets (Table 3.1).  
 
Our findings illuminate the potential importance of X in autoimmune disease, show that X-based 
analysis can be used to fruitfully mine existing datasets, and provide the tools and incentive for 
others to do the same. Additional XWAS can further elucidate the role of sex chromosomes in 
disease etiology, explore the role of sexual dimorphism and gender disparity in disease, and 
introduce gender-specific diagnosis and gender-specific treatment of complex disease. 
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3.2 Results and Discussion 
3.2.1 Associations of individual X-linked genes with autoimmune disease risk 
We assembled 16 datasets of AID and DPACs for analysis (Table 3.1). For each dataset, we first 
carried out QC that we developed expressly for the X chromosome (Materials and Methods), and 
excluded the pseudoautosomal regions (PARs). We then imputed SNPs across X based on 
whole-genome and whole-exome haplotype data from the 1000 Genomes Project (Materials and 
Methods). Of the 16 datasets, none of the original GWAS published had imputed variants in an 
X-specific manner, and only the Wellcome Trust Case Control Consortium 1 (WT1) datasets 
were analyzed with an X-aware strategy ( !The Wellcome Trust Case Control Consortium 2007). 
We applied three statistical methods to measure disease association for each SNP in each of the 
16 datasets. The 16 datasets can be considered as independent as we ensured none had 
overlapping data (Materials and Methods). First, we utilized logistic regression as commonly 
applied in GWAS, where X-inactivation is accounted for by considering hemizygous males as 
equivalent to female homozygotes (FM02 test) (Materials and Methods). Second, we employed 
two similar sex-stratified (i.e. separately for each sex) regression analyses and combined them 
into a single test of association using Fisher’s method (FMF.comb test) or Stouffer’s method 
(FMS.comb). FMF.comb accommodates the possibility of differential effect size and direction 
between males and females and is not affected by the allele coding in males, while FMS.comb takes 
in account both the sample size of males versus females and the direction of effect (Materials and 
Methods). We employed EIGENSOFT (Patterson, Price et al. 2006) to remove individuals of 
non-European descent and correct for potential population stratification. Following this 
correction, QQ (quantile-quantile) plots of the two tests across all SNPs in each dataset revealed 
no systematic bias though a couple studies display reduced power than expected (Supplementary 
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Fig. 3.S1).  
 
We combined all SNP-level test statistics spanning individual genes to obtain gene-level test 
statistics (gene-based tests) in each of the 16 datasets for the FM02, FMF.comb and FMS.comb tests. 
We considered genes by unique transcripts and—to also consider cis-regulatory elements—
included a flanking 15 kilobase (kb) window on each side of the transcribed region. This test 
aggregates signals across all SNPs in each of these genes, while accounting for the structure of 
linkage disequilibrium (LD) within each gene (Liu, McRae et al. 2010). We combined SNP 
statistics with the truncated tail strength (Jiang, Zhang et al. 2011) and truncated product 
(Zaykin, Zhivotovsky et al. 2002) methods. Rather than consider only the single SNP with the 
strongest signal, these methods combine signals from the most significant SNPs, thus improving 
statistical power. This is particularly true for cases where a gene contains multiple risk alleles or 
where the causal SNP cannot itself be tested (Materials and Methods) (Huang, Chanda et al. 
2011; Ma, Clark et al. 2013). Detailed results based on the SNP-level tests before combination 
into gene-based tests, are provided in Supplementary Text, Supplementary Figure 3.S2, and 
Supplementary Table 3.S1. We considered for replication genes with significance of P < 10-3 as 
no gene was significant based upon a strict Bonferroni correction for the number of genes tested 
in each dataset (Table 3.1). We first attempted replication in a different dataset of the same or 
related disease, if such a dataset was available for our analysis (Table 3.1). Otherwise, motivated 
by the shared pathogenicity of different AID (Sirota, Schaub et al. 2009; Cotsapas, Voight et al. 
2011; Sivakumaran, Agakov et al. 2011) (which is also supported by our following results), we 
attempted replication in all other datasets considered herein (Table 3.1).  
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We detected 54 unique genes that passed the initial criteria for discovery (P < 10-3) in one or 
more of the 16 datasets, using the three types of tests, FM02, FMF.comb and FMS.comb. Of these, 38 
genes passed the threshold in the FM02 test, 22 in FMF.comb test and 34 in the FMS.comb test 
(Supplementary Tables S2-S3), with overlap between the three sets. Of the 54 genes, we 
successfully replicated 5 in a different dataset of the same or related disease (Fig. 3.1a-c, 
Supplementary Table 3.S4) following a Bonferroni correction for the number of genes we 
attempted to replicate within each dataset (Supplementary Tables 3.S2-3.S3). These include 3 
genes (FOXP3, PPP1R3F and GAGE10) in LD for the FM02 test and 3 genes (PPP1R3F, 
GAGE12H and GAGE10) in LD for the FMS.comb test that are associated with vitiligo, a common 
autoimmune disorder that is manifested in patches of depigmented skin due to abnormal 
destruction of melanocytes. All genes still successfully replicated when we repeated the gene-
based analysis without the flanking region of 15 kb around each gene, though it remains unclear 
whether these represent independent signals or are still in LD with the same, potentially causal, 
variant(s). FOXP3 has also been previously associated to vitiligo in a candidate gene approach 
(Birlea, Jin et al. 2011) and may be of particular interest as it is involved with leukocyte 
homeostasis, which includes negative regulation of T-cell-mediated immunity and regulation of 
leukocyte proliferation (Fontenot, Gavin et al. 2003; Tang and Bluestone 2008). Defects in the 
gene are also a known cause for an X-linked Mendelian autoimmunity-immunodeficiency 
syndrome (IPEX - immunodysregulation polyendocrinopathy enteropathy X-linked syndrome) 
(Bennett, Christie et al. 2001).  
 
In CD, an inflammatory bowel disorder with inflammation in the ileum and some regions of the 
colon, we discovered an association of the gene ARHGEF6 and further replicated the signal in 
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the Wellcome Trust Case Control Consortium 2 ulcerative colitis (WT2 UC) dataset. ARHGEF6 
binds to a major surface protein of H. pylori (Baek, Lim et al. 2007), which is a gastric bacterium 
that may play a role in inflammatory bowel diseases (Luther, Dave et al. 2010; Jin, Chen et al. 
2013).  
 
Another gene, CENPI, has been independently associated with three diseases (amyotrophic 
lateral sclerosis (ALS), celiac disease, and vitiligo) (Supplementary Table 3.S5), with a 
combined p-value of 2.13x10-7 (Fisher’s method). The association of CENPI when combining 
across all 16 datasets is still significant following a conservative Bonferroni correction for the 
number of genes we tested (P = 2.71x10-5). CENPI is a member of a protein complex that is 
recruited to the centromeres to participate in the assembly of kinetochore proteins, as well as 
generate spindle assembly checkpoint signals required for cell progression through mitosis 
(Matson, Demirel et al. 2012). A previous study demonstrated that it is targeted by the immune 
system in some scleroderma patients (Hamdouch, Rodriguez et al. 2011). Additionally, other 
genes in the same family have been previously associated with immune-related diseases, such as 
multiple sclerosis (CENPC1) (Baranzini, Wang et al. 2009) and ALS (CENPV) (Ahmeti, Ajroud-
Driss et al. 2013).  These findings combined, suggest a possible general role for CENPI in 
autoimmunity. Motivated by this association of CENPI in multiple AID and DPACs, as well as 
previous evidence of shared pathogenicity across different AID87,88, we sought to replicate genes 
in diseases different than the ones in which they had been discovered. We successfully replicated 
17 additional genes in this fashion, which we present here as suggestive evidence of these genes 
having a role in autoimmunity or immune-response (Fig. 3.1a-c, Supplementary Table 3.S6).  
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3.2.2 The sex-specific nature of X-linked genes implicated in autoimmune disease risk 
 If X underlies part of the sexual dimorphism in complex diseases, then we would expect some 
genes to have significantly different effect sizes between males and females. We tested this 
expectation across all SNPs and datasets (Materials and Methods). QQ-plots revealed no 
systematic inflation (Supplementary Fig. 3.S3). As with our analysis above, we combined these 
p-values to obtain gene-based tests of sex-differentiated effect size. This aims to capture a 
scenario whereby SNPs within the tested gene display different effects in males and females, 
with no constraint on a consistent direction of effect differences. We discovered and replicated 
C1GALT1C1 as exhibiting sex-differentiated effect size in risk of IBD (Fig. 3.1d, Supplementary 
Table 3.S4; Supplementary Table 3.S7). C1GALT1C1 (also known as Cosmc) is necessary for 
the synthesis of many O-glycan proteins (Ju and Cummings 2005), which are components of 
several antigents. Defects of C1GALT1C1 may cause Tn Syndrome (a hematological disorder) 
(Thurnher, Clausen et al. 1992). When considering replication in datasets of other diseases, we 
found that both CENPI and MCF2, which we previously associated to risk of AID in our 
analyses above, also showed significant sex-differentiated effect sizes (Fig. 3.1d, Supplementary 
Table 3.S6). 
 
We further found that some X-linked genes associated to AID exhibit differences in expression 
between males and females. Using a comprehensive dataset of whole blood gene expression 
from 881 individuals (409 males and 472 females; Materials and Methods), we assayed gene 
expression in males and females separately. Overall, X-linked genes that we analyzed exhibit a 
2.55-fold enrichment for differential expression between males and females as compared to all 
genes in the human genome (P=6.29x10-8), with XIST, the gene responsible for X-inactivation in 
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females, displaying the most significant difference between males and females among all X-
linked genes (P<<10-16). Within the associated genes, four have significant sex-differential gene 
expression: ITM2A (4.54x10-9), EFHC2 (4.86x10-5), PPP1R3F (7.06x10-5) and BEND2 
(4.17x10-4) (Materials and Methods). Importantly, as described above, we discovered that two of 
these genes (EFHC2 and BEND2) exhibit sex-differentiated effect sizes, with the results herein 
proposing these to potentially be related to sex-differential expression patterns.   
 
3.2.3 Biological relevance of disease risk genes 
As the X chromosome carries on it a set of unique genes, we set out to explore the biological 
function of our associated disease risk genes. By investigating the gene expression patterns of 13 
genes for which we could obtain tissue-specific expression data, (Materials and Methods), we 
found that three genes show the highest expression in cells and organs directly involved in the 
immune system (Fig. 3.3): ARHGEF6 is expressed in T-cells, IL13RA1 in CD14+ monocytes, 
and ITM2A in the thymus (in which T-cells develop). In addition, three other genes, MCF2 
(associated with vitiligo), NAPL12 and TMEM35 (associated with ALS) exhibit the highest 
expression levels in the pineal gland (a four-fold enrichment relative to all X-linked genes we 
tested, P=3.35x10-3). The pineal gland produces and secretes melatonin, which interacts with the 
immune system (Calvo, Gonzalez-Yanes et al. 2013; Pohanka 2013) and has been implicated in 
the diseases we associated these genes to (Slominski, Paus et al. 1989; Jacob, Poeggeler et al. 
2002; Sospedra and Martin 2005; Terry, Villinger et al. 2009; Dibner, Schibler et al. 2010; 
Calvo, Gonzalez-Yanes et al. 2013), as well as suggested as a possible treatment for ALS 
(Weishaupt, Bartels et al. 2006). In addition to these genes, NLGNX4, which is associated with 
psoriasis in the current study, is primarily expressed in the amygdala. Although the amygdala is 
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not known to affect the immune system, it mediates many physiological responses to stress 
(Roozendaal, McEwen et al. 2009; Mahan and Ressler 2012), which is believed to play a 
significant role in susceptibility to psoriasis (Heller, Lee et al. 2011). 
 
The nature of the diseases we analyzed and the uniqueness of X led us to an a priori hypothesis 
that genes of a specific biological nature contribute to X-linked AD disease risk. Hence, we 
tested for association of whole gene sets with each AD or DPAC (Materials and Methods). The 
first two sets include X-linked genes with immune-related function as defined by the KEGG/GO 
or Panther databases (Materials and Methods). The third set includes the 19 non-
pseudoautosomal X genes with functional Y homologs. While analysis of the immune-related 
gene sets was motivated by the nature of the diseases, our test of the latter set was motivated by 
an evolutionary perspective. X genes with functional Y homologs are more likely to be under 
functional constraint (Wilson Sayres and Makova 2013) and thus, may be more likely to play a 
part in disease etiology. We associated the Panther immunity gene set to vitiligo risk in both 
vitiligo studies (Vitiligo GWAS1 and GWAS2) and one type-2 diabetes study (T2D GENEVA), 
and the KEGG/GO set in Vitiligo GWAS1 (Table 3.2). Furthermore, genes with functional Y 
homologs contribute to psoriasis (CASP dataset) and vitiligo (Vitiligo GWAS1) disease risk 
(Table 3.2). These genes are likely to encode biologically conserved functions, as their Y 
homologs have retained function despite loss of recombination with X (which has led to 
progressive degeneration of the Y chromosome over the course of the evolution of the 
supercohort Theria) (Wilson Sayres and Makova 2013) 
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3.2.4 Relation between associated disease risk genes 
Investigating the co-expression of associated disease-risk genes across the 881 individuals 
(Materials and Methods) we found that 3.9% of all X-linked gene pairs exhibit significant 
positively correlated gene expression patterns. Pairs of genes associated with any AID or DPAC 
exhibit significant positively correlated expression in 8% of the cases - a significantly higher 
fraction relative to X-linked genes overall (P=1.53x10-3). This suggests that these genes are more 
likely to work in concert and perhaps interact in the same pathways or cellular networks. Indeed, 
using data from protein-protein or genetic interactions (Materials and Methods), we found that 
all but four are included in the same interaction network  (Fig. 3.4). Perhaps not surprisingly, we 
found several of the significantly enriched pathways relate to immune response or specific 
immune-related disorders or diseases (Table 3.3). Of the remaining pathways, the regulation of 
actin cytoskeleton has also been found to influence the developing morphology and movement of 
T-cells, while the TGF-beta signaling pathway and the ECF-receptor interaction pathway can 
both mediate apoptosis (Lukashev and Werb 1998; Schuster and Krieglstein 2002). Finally, the 
Wnt signaling pathway is generally involved in cell development processes, such as cell-fate 
determination and cell differentiation (Logan and Nusse 2004). It also plays a role in immature 
T-cell and B-cell proliferation, migration of peripheral T-cells, and modulation of antigen 
presenting cells such as dendritic cells (Staal, Luis et al. 2008). 
 
3.2.5 Concluding remarks 
In this study, we applied an X-tailored analysis pipeline to 16 different GWAS datasets (Table 
3.1), discovered and replicated several genes associated with autoimmune disease risk. Multiple 
additional lines of evidence point to some of these genes having immune-related functions, 
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including expression in immune-related tissues (Figs. 3.2-3.3), in addition to enrichment for 
these genes and their interacting partners in immune related pathways (Table 3.3). Beyond 
immune function, several of the genes we associated with disease risk (IL13RA1, ARHGEF6, 
MCF2) are also involved in regulation of apoptosis. Apoptosis has long been suspected of 
playing a role in AID (Eguchi 2001; Kawakami and Eguchi 2002; Mason, Lin et al. 2013) and 
shows strong evidence for involvement in the etiology of vitiligo90, psoriasis (Weatherhead, Farr 
et al. 2011) and rheumatoid arthritis (Li, Ma et al. 2014). Our analyses also highlight the sex 
specific nature of associated disease risk genes shedding light on the sexual dimorphism of some 
autoimmune and immune-mediated diseases.  
 
The X chromosome has received special attention in GWAS during the past year (Conde, Foo et 
al. 2013; Wise, Gyi et al. 2013; Konig, Loley et al. 2014; Tukiainen, Pirinen et al. 2014). Our 
results highlight chromosome X’s contribution to sex-differences in disease risk and yield new 
avenues for potential functional follow-up. More generally, our study illustrates that with the 
right tools and methodology, new discoveries regarding the role of X in complex disease and 
sexual dimorphism can be made, even with existing, array-based GWAS datasets. To enable 
researchers to make many additional such discoveries by analyzing this unique chromosome in 
the context of existing and emerging genome-wide association studies, we have released our 
software for handling chromosome X (Chang, Gao et al.), which we provide as an extension of 
PLINK (Purcell, Neale et al. 2007). Further expansions of this initial software can take unique X-
related features to further develop X-tailored methods such as methods that rely on X-
inactivation and on the availability of phased X haplotypes in males. 
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3.3 Materials and Methods 
3.3.1 Datasets 
We obtained the following datasets from dbGaP: ALS Finland (Laaksovirta, Peuralinna et al. 
2010) (phs000344), ALS Irish (Cronin, Berger et al. 2008) (phs000127), CIDR Celiac disease 
(Ahn, Ding et al. 2012) (phs000274), MScc (Baranzini, Wang et al. 2009) (phs000171), Vitiligo 
GWAS1 (Jin, Birlea et al. 2010) (phs000224), NIDDK CD (Duerr, Taylor et al. 2006) 
(phs000130), CASP (Nair, Duffin et al. 2009) (phs000019), and GENEVA T2D (Qi, Cornelis et 
al. 2010) (phs000091). The Vitiligo GWAS2 (Jin, Birlea et al. 2012) dataset was provided by 
R.S. Both vitiligo datasets contained case data only. Therefore, we obtained the following 
additional control datasets from dbGaP: PanScan (Amundadottir, Kraft et al. 2009; Petersen, 
Amundadottir et al. 2010) (phs000206), National Institute on Aging Alzheimer’s study (Lee, 
Cheng et al. 2008) (phs000168), CIDR bone fragility (Estrada, Styrkarsdottir et al. 2012) 
(phs000138), COGA (Bierut, Saccone et al. 2002) (phs000125), and SAGE (Bierut, Saccone et 
al. 2002; Bierut 2007; Bierut, Strickland et al. 2008) (phs000092). Only samples with the 
“general research consent” designation in the control datasets were used as controls for studying 
vitiligo. These samples were randomly distributed between the two vitiligo datasets.  
 
Additional datasets were obtained from the Wellcome Trust Case Control Consortium (WT): all 
WT1 ( !The Wellcome Trust Case Control Consortium 2007) datasets, WT2 ankyolosing 
spondylitis (AS) (Evans, Spencer et al. 2011), WT2 ulcerative colitis (UC) (Barrett, Lee et al. 
2009) and WT2 multiple sclerosis (MS) (Sawcer, Hellenthal et al. 2011). In order to run meta-
analysis and independently replicate signals, we ensured that none of these datasets had 
overlapping controls. To accomplish this, we recruited additional control data from the WT1 
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hypertension (HT), bipolar (BP), and cardiovascular disease (CAD) case data. These samples 
were randomly distributed to the four WT1 datasets, though only BP samples were used as 
controls for WT1 T2D due to potential shared disease etiology between T2D, CAD and HT. The 
WT1 National Birth Registry (NBS) control data was also randomly distributed to the four WT1 
datasets.  We randomly distributed the 58 Birth Cohort (58BC) control samples, along with any 
new NBS samples not present in the WT1 data, between WT2 datasets.  
 
3.3.2 Quality Control (QC) 
Our pipeline for X-wide association studies (XWAS) begins with a number of quality control 
steps, some of which are specific to the X chromosome. First, we removed samples that we 
inferred to be related, had > 10% missing genotypes, and those with reported sex that did not 
match the heterozygosity rates observed on chromosome X. We additionally filtered variants 
with >10% missingness, variants with a minor allele frequency (MAF) < 0.005, variants for 
which missingness was significantly correlated with phenotype (P<1x10-4). X-specific QC steps 
included filtering variants not in Hardy-Weinberg equilibrium in females (P<1x10-4), removing 
variants that had significantly different MAF between males and females in control individuals; 
and removal of the pseudoautosomal regions (PARs). 
 
3.3.3 Correction for population stratification 
To assess and adjust for potential population stratification we ran principal component analysis 
(PCA) using EIGENSOFT (Patterson, Price et al. 2006) after pruning for linkage disequilibrium 
(LD) and removing large LD blocks (Novembre, Johnson et al. 2008). Individuals inferred to be 
of non-European ancestry were removed from all subsequent analysis. For the datasets analyzed 
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here (of European ancestry), we found that correction for population stratification is more 
accurate when based on the autosomes than on X alone due to the smaller number SNPs used to 
infer structure based on X. This observation holds as long as enough autosomal principal 
components (PCs) are considered. Thus, in our subsequent analyses, only the first ten autosomal 
derived PCs were used to assess and correct for population stratification. Sex-biased 
demographic events though, including sex-differential population structure of males and females, 
such as events proposed for human populations (Hammer, Mendez et al. 2008; Keinan and Reich 
2010; Heyer, Chaix et al. 2012), are expected to lead to differential population structure on X 
and the autosomes. Hence, the problem of population stratification can be different between the 
two genomic compartments. In theory, this suggests that correction for population stratification 
in XWAS should be based on inference of population structure utilizing the X chromosome 
alone. Given this, we anticipate cases—in other populations or where more data is available for 
X—in which correction for population stratification based on X alone could potentially be more 
accurate for XWAS. 
 
3.3.4 Imputation 
Imputation was carried out with IMPUTE2 (Howie, Donnelly et al. 2009) version 2.2.2 based on 
1000 Genomes Project (Abecasis, Auton et al. 2012) whole-genome and whole-exome (October 
2011 release) haplotype data. One of the features added in the second version of impute 
(IMPUTE2) is the assumption of a 25% reduction in the effective population size (Ne) when 
imputing variants on the X chromosome. As recommended by the authors IMPUTE2, Ne was set 
to 20,000 and variants with MAF in Europeans < 0.005 were not imputed. Based on the output of 
IMPUTE2, we excluded variants with an imputation quality < 0.5 and variants that did not pass 
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the above QC criteria (see Quality Control). Table 3.1 displays the number of SNPs we 
considered in each dataset following imputation and these additional QC steps. 
 
3.3.5 Single marker association analysis 
In the first test we assume complete X-inactivation and similar effect size between males and 
females. While females are considered to have 0, 1, or 2 copies of an allele (as in the autosomes), 
males are considered to have 0 or 2 copies of the same allele.  Thus, male hemizygotes are 
equivalent to female homozygous states. This test is currently implemented in PLINK (Purcell, 
Neale et al. 2007) as the –xchr-model 2 option, termed FM02 in this study. In the second test, 
male and female data are analyzed separately (with males coded as either having 0 or 2 copies of 
an allele as above). The female only and male only measures of significance are then combined 
using either Fisher’s (Fisher 1925) method or a weighted Stouffer’s method (Stouffer, Suchman 
et al. 1949), with weighting determined by sample size (Willer, Li et al. 2010) to obtain the 
FMF.comb and the FMS.comb test association p-values. Fisher’s method combines the p-values 
themselves, while Stouffer’s method combines test statistics, taking into account both the sample 
size and direction of effect for males and females. Ten PCs were added as covariates to account 
for potential population stratification. Principal component covariates were not added to the 
regression model for the amyotrophic lateral sclerosis (ALS) Finland, ALS Irish, and CASP 
datasets as no inflated p-values were observed in these studies (Supplementary Fig. 3.S1).   
 
3.3.6 Gene-based analysis 
Gene-based association analysis was carried out in the general framework of VEGAS (Liu, 
McRae et al. 2010). We briefly summarize the method here, though a more detailed description 
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can be found in (Liu, McRae et al. 2010). As SNPs in a gene are in closer proximity with each 
other, they are likely to be in LD and thus have correlated test statistics. VEGAS accounts for 
this correlation by utilizing the LD between SNPs in a gene to derive the distribution of test 
statistics (Liu, McRae et al. 2010). More specifically, n statistics are then randomly drawn from a 
multivariate normal distribution with a mean of 0 and a n x n covariance matrix corresponding to 
the pairwise LD between SNPs mapped to the gene, where n represents the number of SNPs in a 
gene. These n statistics are then combined via summation. Here, we have implemented a slight 
modification to this procedure. In this study, we combined p-values derived from the simulated 
test statistics with either the truncated tail strength (Jiang, Zhang et al. 2011) or the truncated 
product (Zaykin, Zhivotovsky et al. 2002) method, which have been suggested to be more 
powerful than other tests in some scenarios (Huang, Chanda et al. 2011; Ma, Clark et al. 2013). 
The gene-based p-value was calculated as the proportion of simulated statistics that were as 
extreme or more extreme than the observed statistic. To increase time efficiency of the 
simulation procedure, adaptive simulations were implemented as in VEGAS (Liu, McRae et al. 
2010). A list of X-linked genes and their positions was obtained from UCSC “knownCanonical” 
transcript ID track (http://genome.ucsc.edu/cgi-bin/hgTrackUi?db=hg19&g=knownGene). SNPs 
were mapped to a gene if they were within 15 kilobases (kb) of a gene’s start or end positions.  
 
3.3.7 Sex-difference analysis 
The difference in the effect size between males and females at each SNP was assayed using a t-
statistic as calculated below (Randall, Winkler et al. 2013): 
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SE is in the standard error in males or females, and r is the Spearman rank correlation coefficient 
between log(ORmale) and log(ORfemale) across all X-linked SNPs. The odds ratio in males is 
estimated with 02 coding for male genotypes as in the FM02 test. This test is most powered to 
detect variants with opposing effects in males versus females, though it will also capture cases 
where the effects are in the same direction though significantly different in magnitude.  
 
3.3.8 Gene expression analysis 
Whole blood gene expression data for 881 samples (409 males, 472 females) from the Rotterdam 
Study III (Hofman, Breteler et al. 2009) was downloaded from Gene Expression Omnibus 
(Barrett, Wilhite et al. 2013) (accession GSE33828). Expression data was available for 802 of 
the genes studied in our XWAS. For each gene, we tested for differential expression between 
males and females using the Wilcoxon rank sum test across individuals and applied Bonferroni 
correction to its p-values. Using a hypergeometric test, we also assayed whether the 802 X-
linked genes analyzed in our study are more often differentially expressed between males and 
females as compared to all genes genome-wide. In addition, we assessed how many of the genes 
that were associated and replicated (20 genes with expression data) showed significant 
differential expression between males and females (after Bonferroni correction for the number of 
associated and replicated genes). To assess co-expression between X-linked genes, we calculated 
the non-parametric Spearman correlation coefficient between the expression of each pair of 
genes across the set of 881 individuals. Enrichment of significant co-expression within the set of 
20 associated genes as compared to all 802 genes was tested using a hypergeometric test.  
 
For analysis of tissue-specific gene expression, we obtained the Human GNF1H tissue-specific 
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expression dataset (Su, Wiltshire et al. 2004) via the BioGPS website (Wu, Macleod et al. 2013). 
After excluding fetal and cancer tissues, we were left with expression data across 74 tissues for 
504 of the genes studied in our XWAS, including 14 of the genes with evidence of association 
(Fig. 3.1). For each gene, we obtained a normalized z-score value for its expression in each tissue 
by normalizing its expression by the average and standard deviation of the expression of that 
gene across all tissues. 
 
3.3.9 Network analysis 
A network of interacting genes was assembled in GeneMANIA using confirmed and predicted 
genetic and protein interactions (Warde-Farley, Donaldson et al. 2010) with a seed list of the 22 
protein-coding genes within the list of associated genes (Fig. 3.1). Up to 100 genes were added 
with a maximum of 20 attributes. Scores for interactions were weighted equally by network. This 
scoring allows for querying interactions between genes while minimizing bias from obtaining 
more hits in well-studied pathways. A list of unique genes within this interactome was extracted 
as input to WebGestalt (Zhang, Kirov et al. 2005; Wang, Duncan et al. 2013) to discover the ten 
most significantly enriched pathways in the KEGG (Kanehisa and Goto 2000) database. 
Enrichment was assessed with the hypergeometric test (Wang, Duncan et al. 2013) and reported 
p-values were adjusted for multiple testing using the Benjamini-Hochberg correction. Pathways 
were required to have a minimum of two genes.   
 
3.3.10 Gene-set analysis 
We additionally tested whether SNPs in a set of genes were collectively associated with disease. 
To accomplish this, we modified the gene-based analysis above to draw from multiple 
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multivariate normal (MVN) distributions, each with their own covariance matrix corresponding 
to the LD between SNPs in each gene within the gene-set. Comparing p-values derived from 100 
phenotypic permutations to this simulation procedure revealed highly correlated significance 
values (Supplementary Fig. 3.S4-3.S5). We thus only present results from our simulation 
procedure.  
 
We manually curated a set of immune-related genes from the KEGG (Kanehisa and Goto 2000) 
pathways and Gene Ontology (GO) (Ashburner, Ball et al. 2000) Biological Function categories.  
To do this we mined the KEGG and GO databases using 15 and 14 categories, respectively, that 
are particularly relevant for autoimmune response.  We subsequently removed eight genes from 
this list that we felt were either too generalized (e.g. cell cycle genes) or too specific (e.g. F8 and 
F9 blood coagulation genes) to obtain a final list of 27 genes (Supplementary Table 3.S9). The 
Panther immune gene set was obtained by including genes in the category of “immune system 
processes” in the Panther database (Thomas, Campbell et al. 2003). The XY homolog gene set 
was obtained from Wilson-Sayres and Makova (Wilson Sayres and Makova 2013). 
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3.4 Supplementary Text 
 
The single nucleotide polymorphism (SNP) association analysis, including imputed SNPs, 
identified 42 SNPs significantly associated with their respective disease following a conservative 
Bonferroni correction for the number of tests (Supplementary Fig. 3.S2a, Table 3.S1). Of these, 
14 SNPs in the same locus form a clear peak (Supplementary Fig. 3.S2b) in their association 
with vitiligo (Vitiligo GWAS1 dataset). Vitiligo is a common autoimmune disorder in which the 
destruction of melanocytes (pigment producing cells located in the basal epidermis) results in 
depigmented skin. The associated locus is 17 kilobases (kb) away from a weakly expressed 
retrotransposed gene (retro-HSPA8) that is of 98% similarity to its parent gene, HSPA8, on 
chromosome 11. HSPA8 encodes a member of the heat shock protein 70 family and functions as 
a chaperone to bind nascent polypeptides and enable correct folding. Heat shock proteins have 
been previously implicated in autoimmune disease(Winfield and Jarjour 1991; Rauch, San 
Martin et al. 1995; Ludwig, Stahl et al. 1999; Naumann, Hempel et al. 2001; Routsias and 
Tzioufas 2006). In particular, a role for inducible heat shock protein 70 has been suggested in 
vitiligo(Mosenson, Zloza et al. 2012; Abdou, Maraee et al. 2013; Mosenson, Eby et al. 2013). 
Though this region did not replicate in our second vitiligo dataset, the biological relevance of this 
region warrants further investigation in a larger, better powered replication study. Another clear 
association peak was observed for the Wellcome Trust Case Control Consortium 2 ulcerative 
colitis (WT2 UC) (Supplementary Fig. 3.S1c) for intronic variants of BCOR. BCOR encodes a 
co-repressor of BCL-6, which regulates apoptosis(Huynh, Fischle et al. 2000). However, none of 
these candidate associations replicated in other GWAS datasets for the same or related diseases, 
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possibly due to small sample sizes and thus insufficient power (Table 3.1).  
 
There is abundant evidence that many autoimmune and immune-related disorders share some 
genetic etiology(Sirota, Schaub et al. 2009; Cotsapas, Voight et al. 2011; Solovieff, Cotsapas et 
al. 2013; Chang and Keinan 2014). While these studies have focused on autosomal variants, this 
may also be the case for chromosome X. We therefore used PLINK(Purcell, Neale et al. 2007) to 
perform a fixed-effects meta-analysis on several subsets of our diseases.  We performed these 
analyses using the p-values generated from the FM02 test.  Specifically, we applied this analysis 
to the following disease sets (see Table 3.1 for dataset designations): (i) all classic autoimmune 
diseases: CIDR celiac disease, WT1 CD, WT1 RA, WT1 T1D, WT2 UC, WT2AS, WT2 MS, 
CASP; (ii) WT2 AS, WT1 RA, WT1 T1D, CIDR celiac disease(Sirota, Schaub et al. 2009); (iii) 
classical neurological disorders: ALS Finland, ALS Irish, WT2 MS, MS case control (iv) 
diabetes: WT1 T1D, WT1 T2D; (v) irritable bowel disease: WT1 CD, NIDDK CD, WT2 UC; 
(vi) and skin related disorders: Vitiligo GWAS1 and CASP.   
  
We found 4 regions containing SNPs with P < 1x10-4 in three of the disease groups 
(Supplementary Table 3.10a-c). While not significant after a conservative Bonferroni correction 
for the number of SNPs tested on X, the most significant SNP in the inflammatory bowel 
disorder disease group (P= 1.73x10-5) is located ~38 kb from CD40LG, which encodes a protein 
expressed on the surface of T-cells (Supplementary Table 3.10a-c). Furthermore, one of the most 
significant SNPs in the psoriasis and vitiligo meta-analysis (rs11797576, P = 7.13x10-5) is 
located 50 kb from EGFL6, which encodes an epidermal growth factor (Supplementary Table 
3.10a-c).  
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We further tested for a significant difference in effect size between males and females (see 
Methods in the main text). We found one significant SNP (rs200718, P = 1.51x10-7) in Vitiligo 
GWAS1. Association of this SNP was not replicated in Vitiligo GWAS2 due to its very low 
minor allele frequency (MAF < 0.003). We thus assayed whether the nearby SNP rs5976539, in 
moderate LD with rs200718 (D’ = 0.306), was associated in Vitiligo GWAS2, but did not find 
evidence for a significant difference in effect size between males and females (P = 0.920). 
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3.5 Figures 
 
Figure 3.1. X-linked genes associated with autoimmune disease risk.  
All genes that showed evidence of association in a gene-based test (P<10-3), and replicated in 
another dataset are shown for the a) FMS.comb b) FMF.comb c) FM02 and d) sex-differentiated effect 
size tests (Materials and Methods). Dataset names, as described in Table 3.1, are displayed on 
the x-axis and gene names on the y-axis. For each gene, the more significant p-value of the 
truncated tail strength and truncated product methods is displayed on a –log10 scale according to 
the enclosed color scale. A “*” represents the discovery dataset, while “**” indicates the 
replication dataset/s. These appear in grey when the discovery and replication are in datasets of 
the same disease (or across the related Crohn’s disease and ulcerative colitis). Numerical values 
corresponding to this table are presented in Table 3.S4 and 3.S6.
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Figure 3.2. X-linked disease risk genes are differentially expressed between tissues. 
X-axis presents 13 out of the associated X-linked genes for which gene expression data was available for analysis. For each, a z-score 
is presented for the deviation of expression in each of 74 tissues (y-axis) from the average expression of that gene across all tissues 
(Materials and Methods). For comparison, the last column shows average expression in each tissue across all X-linked genes that were 
tested as part of our analyses. Several associated genes exhibit significantly higher expression in immune-related tissues (see main 
text). 
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Figure 3.3. Three X-linked disease risk genes show high expression in immune-related 
tissues and cells.  
ARHGEF6, IL13RA1, and ITM2A show expression greater than 4 standard deviations above the 
average expression of these genes in T-cells (highest in CD4+), CD14+ monocytes, and the 
thymus, respectively (Fig. 3.2). Y-axis follows the respective tissues from Figure 3.2 and x-axis 
denotes a z-score for the deviation of expression in each tissue from the average expression of 
that gene. The title of each panel includes the name of the gene and the tissue with the highest 
expression for that gene. 
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Figure 3.4. Interactome of X-linked disease risk genes.  
All 22 associated X-linked protein-coding genes (Fig. 3.1), denoted by black diamonds, together 
with genes that interact with them. Physical interactions refer to documented protein-protein 
interactions. Genetic interactions represent genes where perturbations to one gene affect another. 
Predicted interactions were obtained from orthology to interactions present in other organisms 
(Warde-Farley, Donaldson et al. 2010). All but three genes associated with AID and DPACs 
share interacting partners according to known and predicted interactions (Materials and 
Methods).  
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Figure 3.S1. QQ-plots for single marker association tests.  
Blue triangles denote association p-values for the FMF.comb test, red crosses denote p-values for 
the FMS.comb, while the black points denote association p-values for the FM02 test. P-values are 
plotted in log scale.  
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Figure 3.S2. Significant SNP associations.  
(a) A Manhattan plot of the nominal p-values for the FM02 (upper), FMF.comb (middle), and 
FMS.comb (lower) tests of association for chromosome X SNPs in the 16 datasets. The dotted 
purple lines correspond to the significance threshold for each dataset. The significant 
associations are shown as red diamonds. (b-c) Regional association plots of the association 
results and LD for (b) Vitiligo GWAS1 data set and (c) WT2 UC data set.  Upper: the purple 
dotted line corresponds to the significance threshold, and the significant results are shown as red 
diamonds. Lower: LD structure was plotted using a revised version of the snp.plotter software 
(Luna and Nicodemus 2007). Due to the large number of SNPs in the associated region of 
Vitiligo GWAS1, only every 1 in 10 of the non-significantly associated SNPs are shown. 
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Figure 3.S3. QQ-plots for test of sex-differentiated effect size.  
Similar to Figure 3.S1, where p-values are now displayed for the test of differential effect size 
between males and females.  
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Figure 3.S4. Comparison between simulation derived and permutation derived p-values for 
the gene-set association analysis using the FM02 test statistic.  
r represents Pearson’s correlation coefficient and the significance of the correlation is indicated 
in the parentheses in scientific notation.  
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Figure 3.S5. Comparison between simulation derived and permutation derived p-values for 
the gene-set association analysis using the FMF.comb test statistic. 
Similar to Figure 3.S5 where test statistics for the FMF.comb test are now displayed.  
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3.6 Tables 
Dataset Disease # SNPs # Genes # Cases # Controls 
ALS Finland  
Amyotrophic 
Lateral Sclerosis 
(ALS) 207,947 
 
970 
400 490 
ALS Irish  
Amyotrophic 
Lateral Sclerosis 
(ALS) 219,300 
 
967 
221 210 
Psoriasis CASP  Psoriasis 184,246 953 1,209 1,271 
Celiac Disease 
CIDR  Celiac Disease 187,284 
 
962 1,576 504 
CD NIDDK  
Crohn's Disease 
(CD) 176,072 
 
837 791 922 
CD WT1* 
Crohn's Disease 
(CD) 150,275 
 
930 1,592 1,701 
UC WT2*  
Ulcerative Colitis 
(UC) 196,781 
 
963 2,341 1,699 
MS case control  
Multiple Sclerosis 
(MS) 183,954 
 
842 943 851 
MS WT2*  
Multiple Sclerosis 
(MS) 169,707 
 
962 2,666 1389 
Vitiligo GWAS1  Vitiligo 157,676 958 1,391 4,521 
Vitiligo GWAS2  Vitiligo 187,688 962 415 2,552 
T2D GENEVA  
Type-2 Diabetes 
(T2D) 220,752 
 
971 2,515 2,850 
T2D WT1*  
Type-2 Diabetes 
(T2D) 152,996 
 
927 1,811 1,668 
T1D WT1*  
Type-1 Diabetes 
(T1D) 152,304 
 
926 1,867 1,714 
RA WT1*  
Rheumatoid 
Arthritis (RA) 146,907 
 
925 1,772 1,709 
AS WT2* 
Ankyolosing 
Spondylitis (AS) 200,042 
 
966 1,472 1,260 
 
Table 3.1. GWAS datasets.  
For each of the case-control datasets analyzed in this study, the table lists its name, the disease 
considered, the number of X-linked SNPs (# SNPs), which include imputed SNPs, and the 
number of genes tested in the gene-based test (# Genes). The number of individuals (# Cases and 
# Controls) represents the number of samples following QC. All datasets consist of individuals 
of European ancestry. Though ALS and T2D are not conventionally considered as autoimmune 
diseases, we have included datasets of these diseases due to recent studies pointing to an 
autoimmune component to their etiology (Pagani, Gonzalez et al. 2011; Itariu and Stulnig 2014).  
*As control individuals overlap across these datasets, we only considered non-overlapping 
subsets of them for each of the diseases studied here (Materials and Methods). The size of these 
subsets is indicated under # Controls. 
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Dataset Statistic P-value 
XY homologs gene set 
Psoriasis CASP FMF.comb 0.0088 
Celiac disease CIDR FMF.comb 0.0467 
Vitiligo GWAS1 FMF.comb 0.0063 
Vitiligo GWAS1 FM02 0.0329 
Vitiligo GWAS2 FMF.comb 0.0346 
CD NIDDK FM02 0.017 
CD WT1 FM02 0.0234 
T1D WT1 FMS.comb 0.0302 
Panther immune gene set 
Vitiligo GWAS1 FM02 0.0154 
Vitiligo GWAS1 FMF.comb 0.0387 
Vitiligo GWAS1 FMS.comb 0.0081 
Vitiligo GWAS2 FM02 0.0142 
Vitiligo GWAS2 FMF.comb 0.0448 
Vitiligo GWAS2 FMS.comb 0.0127 
T2D GENEVA FMS.comb 0.0073 
KEGG/GO immune gene set 
Vitiligo GWAS1 FMF.comb 0.002 
Vitiligo GWAS1 FMs.comb 1.64x10-4 
 
Table 3.2. Gene-set associations.  
Three curated gene sets were tested for association to diseases. Datasets with p-values < 0.05 are 
displayed, with bold p-values indicating significant association after multiple testing correction. 
The minimum of the truncated tail strength method and the truncated product method are 
displayed.  
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Pathway Genes P-value 
Regulation of actin 
cytoskeleton 
PAK1, RHOA, PAK3, CDC42, ARHGEF6, 
SOS1, ARHGEF7, PAK2, RDX, GIT1, GNA13, 
TIAM1, ROCK2, FGD1 5.55x10-14 
T-cell receptor 
signaling pathway 
PAK1, RHOA, PAK3, CDC42, SOS1, PAK2, 
IL4, NFATC2, NFATC1, ICOS, NFAT5 2.75x10-13 
Axon guidance 
PAK1, RHOA, PAK3, EPHB2, CDC42, 
NFATC2, NFATC1, NFAT5, ROCK2 4.97x10-11 
Wnt signaling  
SMAD3, SMAD2, RHOA, FZD4, LRP5, 
NFATC2, NFATC1, NFAT5, ROCK2 4.74x10-9 
Systemic lupus 
erythematosus 
H2AFZ, H2AFJ, HIST1H2AH, HIST2H2AB, 
HIST1H2AJ, HIST3H2A, HIST1H2AD 4.34x10-8 
Chemokine signaling 
PAK1, RHOA, CDC42, SOS1, GNB1, TIAM1, 
DOCK2, ROCK2 4.52x10-7 
Focal adhesion 
PAK1, PARVB, RHOA, PAK3, CDC42, SOS1, 
PAK2, ROCK2 6.28x10-7 
TGF-beta signaling 
SMAD3, SMAD2, RHOA, TGFBR2, ROCK2, 
BMPR1B 7.87x10-7 
Pathways in cancer 
SMAD3, SMAD2, RHOA, MDM2, CDC42, 
FZD4, SOS1, RUNX1, TGFBR2 1.74x10-6 
Pancreatic cancer SMAD3, SMAD2, CDC42, ARHGEF6, TGFBR2 6.17X10-6 
 
 
Table 3.3. Gene-enrichment analysis of the interactome.  
Genes associated to AID and DPACs, and their interacting partners (Fig. 3.4) were enriched for 
several immune related pathways. We display the ten most significantly enriched pathways. 
Genes within each pathway that were also within our query set are listed. Displayed p-values are 
adjusted for multiple testing (Materials and Methods).  
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 Dataset SNP FM02 adjusted 
FMF.comb 
adjusted 
FMS.comb 
adjusted 
Vitiligo 
GWAS1 rs2007899 8.24x10-02 1.42x10-01 2.90x10-02 
  rs12852381 3.72x10-02 6.51x10-02 1.34x10-02 
  rs143231802 2.58x10-02 3.62x10-02 6.47x10-03 
  rs4271099 2.99x10-02 5.27x10-02 1.09x10-02 
  rs4335270 6.52x10-02 1.23x10-01 2.67x10-02 
  rs4480250 6.52x10-02 1.23x10-01 2.67x10-02 
  rs17258266 4.90x10-02 7.55x10-02 1.38x10-02 
  rs4300122 8.14x10-02 1.61x10-01 3.62x10-02 
  rs5957594 3.77x10-02 7.27x10-02 1.46x10-02 
  rs34320000 7.87x10-02 1.59x10-01 3.24x10-02 
  rs5957596 1.14x10-01 2.01x10-01 3.92x10-02 
  rs10217856 4.06x10-02 6.84x10-02 1.31x10-02 
  rs5956287 2.71x10-01 2.51x10-01 4.63x10-02 
  rs12834182 2.71x10-01 2.51x10-01 4.63x10-02 
  rs1121546 1.27x10-02 2.79x10-02 6.42x10-03 
  rs5957620 2.17x10-02 3.51x10-02 6.95x10-03 
  rs9887587 2.06x10-02 2.97x10-02 5.71x10-03 
  rs150986507 1.66x10-02 3.31x10-02 6.63x10-03 
  rs12839589 5.00x10-02 8.37x10-02 1.73x10-02 
  rs33977652 2.56x10-01 2.66x10-01 4.86x10-02 
  rs138347087 2.26x10-01 2.39x10-01 4.38x10-02 
  rs35046609 2.91x10-02 4.81x10-02 9.59x10-03 
  rs60669023 2.83x10-01 2.43x10-01 4.50x10-02 
  rs16996189 2.97x10-01 2.60x10-01 4.82x10-02 
  rs5957651 2.98x10-02 5.49x10-02 1.11x10-02 
  rs148797601 6.88x10-03 1.94x10-02 4.33x10-03 
  rs148097246 7.20x10-03 2.04x10-02 4.58x10-03 
          
WT2 AS rs7057428 2.04x10-02 1.0 1.0 
  rs5977756 7.21x10-03 9.05x10-02 2.78x10-01 
          
WT2 UC rs5916435 1.80x10-03 1.22x10-03 2.19x10-04 
  rs5973636 1.15x10-01 4.76x10-02 8.74x10-03 
  rs6610386 3.72x10-02 3.76x10-02 2.24x10-02 
  rs59269143 2.36x10-02 2.26x10-02 1.19x10-02 
  rs5963157 2.73x10-02 2.66x10-02 1.47x10-02 
  rs7060409 7.16x10-03 6.50x10-03 2.64x10-03 
  rs62626573 1.81x10-02 1.63x10-02 4.70x10-03 
  rs35764713 6.96x10-07 3.31x10-09 7.72x10-10 
  rs5969304 7.58x10-05 1.0 1.0 
  rs6643227 3.05x10-03 1.0 1.0 
  rs6655215 2.04x10-04 5.75x10-03 1.03x10-01 
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  rs12008980 8.74x10-05 5.73x10-02 5.85x10-01 
 
Table 3.S1. Significant SNP associations.  
This table lists all significant associations (adjusted P < 0.05) in either the FM02 or FMcomb test. 
P-values are Bonferroni adjusted for the number of SNPs tested as listed in Table 3.1.   
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FMF.comb 
Dataset Gene symbol 
Truncated tail  p-
value 
Truncated 
product p-value 
ALS Finland TAF7L 0.000389 0.0018 
ALS Finland MAGEE2 0.00028 0.0012 
ALS Finland NAP1L2 0.00091 0.00034 
ALS Finland TTC3P1 0.000859 0.0013 
ALS Finland ZDHHC15 0.000413 0.0089 
CASP NLGN4X 0.000887 0.0166 
Celiac disease CIDR CENPI 0.0029 0.000523 
Vitiligo GWAS1 PPP1R3F 0.000114 0.000496 
Vitiligo GWAS1 LINC00632 0.0057 0.000772 
Vitiligo GWAS1 FOXP3 0.000698 0.0015 
Vitiligo GWAS1 BEND2 0.0018 0.000079 
Vitiligo GWAS1 CENPI 0.000155 0.0026 
Vitiligo GWAS2 IL13RA2 0.0021 0.000758 
Vitiligo GWAS2 MCF2 0.00017 0.000576 
CD WT1 CD40LG 0.009 0.000322 
CD WT1 LINC00892 0.0013 0.000088 
T2D WT1 MAGEC1 0.0275 0.000181 
UC WT2 CASK 0.000138 0.0215 
UC WT2 PRPS1 0.000133 0.000194 
UC WT2 PAGE2B 0.0039 0.000012 
UC WT2 SPANXN5 0.00091 0.0013 
MS WT2 MAGEE1 0.000706 0.0023 
FMS.Comb 
ALS Finland TAF7L 0.000547 0.000644 
ALS Finland NAP1L2 0.00057 0.000115 
ALS Finland ITM2A 0.000843 0.000307 
ALS Finland CENPI 0.001271 0.000175 
ALS Finland TMEM35 0.002775 0.000345 
CASP MIR505 <1x10-6 0.001932 
CASP DCX 0.000757 0.00608 
Celiac CIDR IQSEC2 0.00053 0.00071 
CD WT1 Y RNA <1x10-6 0.000052 
CD WT1 LINC00892 0.001739 0.000529 
UC WT2 PRPS1 0.000005 0.000005 
UC WT2 CASK 0.000157 0.021124 
UC WT2 GPR82 0.000209 0.001885 
UC WT2 GPR34 0.000262 0.000162 
UC WT2 PAGE2B 0.000482 0.000002 
UC WT2 NAP1L6 0.001192 0.000429 
MS Case Control RP11-265P11.2 0.00303 0.000855 
Vitiligo GWAS1 PPP1R3F 0.000006 0.000076 
Vitiligo GWAS1 FOXP3 0.000022 0.000149 
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Vitiligo GWAS1 XRCC6P5 0.000081 0.001846 
Vitiligo GWAS1 HUWE1 0.000362 0.001298 
Vitiligo GWAS1 GAGE12H 0.000634 0.000634 
Vitiligo GWAS1 GAGE10 0.001848 0.000266 
Vitiligo GWAS2 MCF2 0.000078 0.000131 
Vitiligo GWAS2 IL13RA2 0.000942 0.000354 
Vitiligo GWAS2 RBMXL3 0.002653 0.000321 
T2D GENEVA ZCCHC12 0.001209 0.000653 
T2D GENEVA  SNORA35 0.002123 0.000454 
T2D GENEVA IL13RA1 0.00635 0.000859 
T2D WT1 MAGEC1 0.026251 0.000068 
T1D WT1 ARX 0.000192 0.000489 
T1D WT1 SRPK3 0.000469 0.008982 
T1D WT1 PLXNB3 0.000487 0.007309 
T1D WT1 RNU6-98P 0.000803 0.001921 
 
Table 3.S2. All genes with either truncated tail or truncated product p-values  < 1x10-3 for 
the FMF.comb and the FMS.comb test. 
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Dataset Gene symbol 
Truncated tail p-
value 
Truncated 
product p-value 
ALS Finland TAF7L 0.000126 0.000332 
ALS Finland NAP1L2 0.000451 0.000038 
ALS Finland ITM2A 0.0021 0.00041 
CASP PGRMC1 <1x10-6 0.0046 
CASP ATP11C 0.000011 0.0092 
CASP DCX 0.000752 0.0048 
CASP MIR505 <1x10-6 0.0039 
MS case control FANCB 0.000052 0.0013 
MS case control RP11-265P11.2 0.0025 0.000423 
Vitiligo GWAS1 PPP1R3F 0.000066 0.000139 
Vitiligo GWAS1 HUWE1 0.000822 0.0027 
Vitiligo GWAS1 LINC00632 0.0137 0.000453 
Vitiligo GWAS1 FOXP3 0.000111 0.000276 
Vitiligo GWAS1 GAGE10 0.0016 0.000403 
Vitiligo GWAS1 CENPI 0.000217 0.001 
Vitiligo GWAS1 MPC1L <1x10-6 <1x10-6 
Vitiligo GWAS1 NAA10 0.00087 0.0028 
Vitiligo GWAS2 IL13RA2 0.001014 0.000526 
Vitiligo GWAS2 MCF2 0.000224 0.000559 
Vitiligo GWAS2 RBMXL3 0.0019 0.000418 
GENEVA T2D RP4-562J12.2 0.000489 0.0013 
CD WT1 ARHGEF6 0.0017 0.000366 
CD WT1 CD40LG 0.0123 0.000223 
CD WT1 LINC00892 0.001572 0.000048 
T1D WT1 SRPK3 0.000327 0.0071 
T1D WT1 ARX 0.000837 0.000565 
T1D WT1 RNU6-98P 0.000716 0.0018 
T1D WT1 PLXNB3 0.000522 0.0076 
T2D WT1 MAGEC1 0.0264 0.000534 
T2D WT1 SASH3 <1x10-6 <1x10-6 
T2D WT1 DUSP9 0.0022 0.000553 
UC WT2 CASK 0.000357 0.0199 
UC WT2 PRPS1 0.000003 0.00001 
UC WT2 NAP1L6 0.001063 0.000057 
UC WT2 PAGE2B 0.012 0.000072 
UC WT2 GPR34 0.0011 0.00061 
 
Table 3.S3. All genes with either truncated tail or truncated product p-values  < 1x10-3 for 
the FM02 test. 
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Table 3.S4. Gene-based associations replicating in similar diseases.  
Table of genes with nominal P < 1x10-3 that replicated in a dataset of the same or similar disease. 
Combined p-values were calculated using Fisher’s method.  
Dataset Gene 
p-value  
(tail, product) Replication dataset 
p-value  
(tail, product) 
combined  
p-value  
(tail, product) 
FM02 
Vitiligo GWAS1 PPP1R3F 
6.60x10-5, 
1.39x10-4 Vitiligo GWAS2 
8.10x10-3, 
2.70x10-3 
8.26x10-6, 
5.93x10-6 
Vitiligo GWAS1 FOXP3 
1.11x10-4, 
2.76x10-4 Vitiligo GWAS2 
5.60x10-3,  
5.40x10-3 
9.50x10-6, 
2.15x10-5 
Vitiligo GWAS1 GAGE10 
1.60x10-3, 
4.03x10-4 Vitiligo GWAS2 
2.80x10-3, 
3.80x10-3 
5.97x10-5, 
2.20x10-5 
CD WT1 ARHGEF6 
1.70x10-3, 
3.66x10-4 UC WT2 
2.30x10-3, 
3.10x10-3 
5.26x10-5, 
1.67x10-5 
FMF.comb 
Vitiligo GWAS1 PPP1R3F 
1.14x10-4, 
4.96x10-4 Vitiligo GWAS2 
3.70x10-3, 
5.80x10-3 
6.61x10-6, 
3.96x10-5 
FMS.comb 
Vitiligo GWAS1 PPP1R3F 
6.0x10-6, 
7.60x10-5 Vitiligo GWAS2 
4.80x10-3, 
1.30x10-3 
5.29x10-7, 
1.69x10-6 
 GAGE12H 
6.34x10-4, 
6.34x10-4 Vitiligo GWAS2 
4.60x10-3, 
4.60x10-3  
4.01x10-5, 
4.01x10-5 
 GAGE10 
1.85x10-3, 
2.66x10-4 Vitiligo GWAS2 
2.90x10-3, 
2.80x10-3 
7.05x10-5, 
1.13x10-5 
Sex Difference  
CD WT1 C1GALT1C1 
1.97x10-3, 
2.63x10-4 UC WT2 
1.39x10-2, 
1.14x10-2 
3.15x10-4, 
4.11x10-5 
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Dataset p-value (tail, product) 
ALS Finland 1.10x10-2, 1.00x10-3 
ALS Irish 2.70x10-2, 1.60x10-2 
CASP 0.91, 0.64 
CIDR Celiac 2.9x10-3, 5.23x10-4 
NIDDK CD 0.17, 0.16 
MS case control 0.91, 0.38 
Vitiligo GWAS1 1.55x10-4, 2.6x10-3 
Vitiligo GWAS2 0.827, 0.65 
Geneva T2D 0.17, 0.19 
WT1 CD 0.83, 0.20 
WT1 T1D 0.85, 0.49 
WT1 RA 0.83, 0.29 
WT1 T2D 0.93, 0.54 
WT2 UC 0.88, 0.45 
WT2 MS 0.81, 0.67 
WT2 AS 0.11, 0.11 
 
Table 3.S5. CENPI association p-values for the FMF.comb test across the 16 datasets.  
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Dataset Gene 
p-value (tail, 
product) Alternate dataset 
p-value (tail, 
product) 
combined  
p-value  
(tail, product) 
FM02 
ALS Finland NAP1L2 
4.51x10-4, 
3.80x10-5 UC WT2 
5.70x10-3, 
3.70x10-3 
3.57x10-5, 
2.36x10-6 
   Vitiligo GWAS1 
1.0x10-2, 
1.40x10-2 
6.00x10-5, 
8.22x10-6 
ALS Finland ITM2A 
2.10x10-3, 
4.10x10-4 Celiac Disease CIDR 
7.90x10-3, 
1.06x10-2 
1.99x10-4, 
5.80x10-5 
MS case control FANCB 
5.20x10-5, 
1.30x10-3 RA WT1 
3.80x10-3, 
1.10x10-2 
3.25x10-6, 
1.74x10-4 
Vitiligo GWAS1 CENPI 
2.17x10-4, 
1.00x10-3 ALS Finland 
2.40x10-3, 
2.00x10-3 
8.06x10-6, 
2.82x10-5 
T2D GENEVA  RP4-562J12.2 
4.89x10-4, 
1.30x10-4 CD NIDDK 
3.41x10-2, 
3.93x10-2 
2.00x10-4, 
5.56x10-4 
   WT2 AS 
5.60x10-2, 
4.30x10-2 
3.15x10-4, 
7.32x10-5 
T2D WT1 MAGEC1 
2.64x10-2, 
5.34x10-4 MS case control 
6.70x10-3, 
8.50x10-3 
1.71x10-3, 
6.04x10-5 
UC WT21  NAP1L6 
1.06x10-3, 
5.70x10-5 ALS Finland 
3.10x10-3, 
5.50x10-3 
4.49x10-5, 
5.01x10-6 
FMF.comb 
CASP NLGN4X 
8.87x10-4, 
1.66x10-2 Vitiligo GWAS2 
1.21x10-2, 
1.31x10-2 
1.34x10-4, 
2.05x10-3 
   CIDR Celiac Disease 
5.10x10-2, 
4.90x10-2 
4.98x10-4, 
6.66x10-3 
Vitiligo GWAS1 BEND2 
1.80x10-3, 
7.90x10-5 T2D WT1 
9.30x20-3, 
1.29x10-2 
2.01x10-4, 
1.51x10-5 
Vitiligo GWAS1 CENPI 
1.55x10-4, 
2.60x10-3 ALS Finland 
1.12x10-2, 
1.00x10-3 
2.48x10-5, 
3.60x10-5 
      Celiac CIDR 
2.90x10-3, 
5.23x10-4 
7.02x10-6, 
1.97x10-5 
Vitiligo GWAS2 MCF2 
1.70x10-4, 
5.76x10-4 MS WT2 
2.31x10-2, 
2.50x10-2 
5.28x10-5, 
1.75x10-4 
CD WT1 LINC00892 
1.30x10-3, 
8.80x10-5 MS WT2 
2.42x10-2, 
1.99x10-2 
3.58x10-4, 
2.50x10-5 
T2D WT1  MAGEC1 
2.75x10-2, 
1.81x10-4 MS case control 
1.42x10-2,  
1.50x10-2 
3.46x10-3, 
3.75x10-5 
MS WT2  MAGEE1 
7.06x10-4, 
2.30x10-3 ALS Finland 
3.23x10-2, 
2.36x10-2 
2.67x10-4, 
5.87x10-4 
FMS.comb 
ALS Finland NAP1L2 
5.7x10-4, 
1.15x10-4 UC WT2 
8.30x10-3, 
7.1x10-3 
6.27x10-5, 
1.23x10-5 
 ITM2A 
8.43x10-4, 
3.07x10-4 Celiac CIDR 
6.5x10-3, 
1.13x10-2 
7.19x10-5, 
4.71x10-5 
 CENPI 
1.27x10-3, 
1.75x10-4 Vitiligo GWAS1 
1.60x10-3, 
5.90x10-3 
2.89x10-5, 
1.53x10-5 
 TMEM35 
2.78x10-3, 
3.45x10-4 Vitiligo GWAS1 
3.80x10-3, 
6.20x10-3 
1.31x10-4, 
3.01x10-5 
CD WT1 LINC00892 
1.73x10-3, 
5.29x10-4 MS WT2 
6.30x10-3, 
6.40x10-3 
1.35x10-4, 
4.60x10-5 
   Vitiligo GWAS1 
2.30x10-2, 
2.89x10-2 
4.41x10-4, 
1.85x10-4 
UC WT2 GPR34 
2.62x10-4, 
1.62x10-4 MS WT2 
5.60x10-3, 
1.10x10-2 
2.12x10-5, 
2.54x10-5 
 NAP1L6 
1.19x10-3, 
4.29x10-4 ALS Finland 
4.00x10-3, 
1.06x10-2  
6.31x10-5, 
6.05x10-5 
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MS case control RP11-265P11.2 
3.03x10-3, 
8.55x10-4 T2D WT1 
4.42x10-2, 
4.68x10-2 
1.32x10-3, 
4.45x10-4 
T2D GENEVA SNORA35 
2.12x10-3, 
4.54x10-4 AS WT2 
2.40x10-3, 
6.70x10-3 
6.71x10-5, 
4.17x10-5 
 IL13RA1 
6.35x10-3, 
8.59x10-4  AS WT2 
6.20x10-3, 
7.20x10-3 
4.39x10-4, 
8.04x10-5 
T2D WT1 MAGEC1 
2.63x10-2, 
6.80x10-5 MS case control 
1.00x10-2, 
1.54x10-2 
2.43x10-3, 
1.55x10-5 
Sex difference  
ALS Finland MAGEE2 
6.5x10-4, 
1.94x10-3 Vitiligo GWAS1 
3.08x10-2, 
1.64x10-2 
2.37x10-4, 
3.61x10-4 
 NDP 
1.41x10-3, 
9.34x10-4 CD WT1 
8.60x10-3, 
1.33x10-2 
1.49x10-4, 
1.53x10-4 
CASP NLGN4X 
2.34x10-4, 
1.65x10-2 Vitiligo GWAS1 
4.52x10-2, 
4.33x10-2 
1.32x10-4, 
5.89x10-3 
Celiac CIDR CENPI 
4.4x10-3, 
2.08x10-4 ALS Finland 
2.03x10-2, 
1.78x10-2 
9.22x10-4, 
5.00x10-5 
   ALS Irish 
9.80x10-3, 
4.40x10-3 
4.88x10-4, 
1.36x10-5 
Vitiligo GWAS1 BEND2 
3.99x10-3, 
1.28x10-4 MS case control 
4.60x10-2, 
5.20x10-2 
1.76x10-3, 
8.60x10-5 
Vitiligo GWAS2 MCF2 
7.00x10-4, 
1.93x10-3 MS WT2 
2.38x10-2, 
2.12x10-2 
2.00x10-4, 
4.54x10-4 
T2D GENEVA EFHC2 
6.09x10-4, 
1.12x10-3 RA WT1 
1.58x10-2, 
1.40x10-3 
1.21x10-4, 
2.42x10-5 
RA WT1 MIR320D2 
8.69x10-3, 
5.68x10-4 ALS Irish 
2.39x10-2, 
2.64x10-2 
1.97x10-3, 
1.82x10-4 
 
Table 3.S6. Gene-based associations replicating in other diseases.  
This table lists genes with nominal P < 1x10-3 that replicated in a disease of a different 
phenotype (Methods). Combined p-values were calculated using Fisher’s method. *We assumed 
a p-value = 1x10-6 in the truncated tail p-value for WT CD when calculating the combined p-
value.
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Dataset Gene symbol 
Truncated tail p-
value 
Truncated product 
p-value 
ALS Finland MAGEE2 6.50x10-4 1.93x10-3 
ALS Finland NDP 1.41x10-3 9.34x10-4 
CASP NLGN4X 2.34x10-4 0.017 
CIDR Celiac CENPI 4.42x10-3 2.08x10-4 
CD WT1 C1GALT1C1 1.97x10-3 2.63x10-4 
UC WT2 SPANXN5 2.72x10-4 3.45x10-4 
UC WT2 XAGE5 2.21x10-3 3.45x10-4 
MS case control ZNF449 7.22x10-4 3.11x10-3 
MS case control BMX 9.91x10-4 2.49x10-3 
Vitiligo GWAS1 BEND2 3.99x10-3 1.28x10-4 
Vitiligo GWAS2 MCF2 7.00x10-4 1.93x10-3 
T2D GENEVA EFHC2 6.09x10-4 1.1x10-3 
T2D WT1 SASH3 <1x10-6 <1x10-6 
T2D WT1 CSTF2 1.63x10-3 8.17x10-4 
T2D WT1 SNORA9 1.63x10-3 8.43x10-4 
T2D WT1 SYTL4 2.27x10-3 3.27x10-4 
RA WT1 MIR320D2 8.69x10-3 5.68x10-4 
 
Table 3.S7. All genes with either the truncated tail or truncated product p-values  < 1x10-3 
for the sex difference test. 
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Gene1 Gene2 r P-value 
ARHGEF6 EFHC2 0.208 4.44x10-10 
ARHGEF6 IL13RA1 0.267 7.46x10-16 
ARHGEF6 PPP1R3F 0.302 4.41x10-20 
BEND2 EFHC2 0.185 3.39x10-8 
C1GALT1C1 EFHC2 0.449 6.80x10-45 
C1GALT1C1 FANCB 0.178 1.12x10-7 
C1GALT1C1 IL13RA1 0.221 3.31x10-11 
C1GALT1C1 ITM2A 0.226 1.27x10-11 
C1GALT1C1 PPP1R3F 0.278 4.57x10-17 
EFHC2 FANCB 0.192 8.49x10-9 
EFHC2 IL13RA1 0.2 2.17x10-9 
EFHC2 ITM2A 0.291 1.13x10-18 
EFHC2 PPP1R3F 0.496 6.03x10-56 
FANCB PPP1R3F 0.183 4.33x10-8 
ITM2A PPP1R3F 0.276 7.89x10-17 
NLGN4X TMEM35 0.193 8.31x10-9 
 
Table 3.S8. Pairs of X-linked genes that are significantly co-expressed.  
We assayed whether associated X-linked genes were significantly co-expressed in samples of 
healthy individuals (see methods in main text). “r” denotes the spearman’s rank correlation 
coefficient, with the p-value listed in the adjacent column (“P-value”).  
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Gene symbol 
OTUD5 
TLR8 
CFP 
RNF128 
PRKX 
APLN 
BTK 
IL3RA 
IKBKG 
IRAK1 
CD40LG 
SH2D1A 
XIAP 
NOX1 
CXCR3 
IL2RG 
EDA 
FOXP3 
WAS 
CYBB 
TAB3 
TLR7 
CD99 
DDX3X 
CSF2RA 
IL9R 
BCAP31 
 
Table 3.S9. List of genes in the KEGG/GO immune gene set.  
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WT2 UC, WT1 CD 
   Original p-value 
Basepair SNP meta-analysis p-value WT2 UC WT1 CD 
135670593 rs2518886 0.00005669 0.005774 0.00003564 
135670824 rs12852548 0.00008458 0.008264 0.0000392 
135671221 rs2807259 0.0000702 0.007347 0.00003564 
135673225 rs5930965 0.00006327 0.00631 0.00003968 
135673610 rs7890404 0.0000173 0.003203 0.00001065 
135674044 rs2807260 0.00004705 0.005757 0.00002743 
135674388 rs2518888 0.00007253 0.007565 0.00003758 
135674543 rs2518889 0.00007253 0.007565 0.00003758 
135675755 rs2518891 0.00006978 0.007508 0.00003558 
135676896 rs2518892 0.00007248 0.007453 0.00003758 
135677559 rs2518893 0.00008051 0.008385 0.00003758 
135677710 rs2518894 0.00006895 0.006859 0.00003758 
135678840 rs2518895 0.00007248 0.007453 0.00003758 
135679053 rs2518896 0.00007248 0.007453 0.00003758 
135679059 rs2518897 0.00007248 0.007453 0.00003758 
135679631 rs2518899 0.00007248 0.007453 0.00003758 
135679960 rs2518900 0.00007248 0.007453 0.00003758 
135680078 rs2518901 0.00006039 0.00753 0.00002765 
135680774 rs2518902 0.00007248 0.007453 0.00003758 
135680970 rs12556398 0.00007972 0.007776 0.00004124 
135681823 rs2518904 0.00007611 0.007371 0.00004155 
135681929 rs73242348 0.00008436 0.008296 0.00004057 
135682887 rs12007112 0.00003256 0.002824 0.00004155 
135683500 rs12012314 0.00007501 0.007918 0.00003735 
135683508 rs73228703 0.00007501 0.007918 0.00003735 
135684162 rs12848318 0.00007801 0.007726 0.00003891 
135685169 rs12559890 0.00007801 0.007726 0.00003891 
135685563 rs12014670 0.00007801 0.007726 0.00003891 
135687540 rs12559116 0.0000454 0.005664 0.00002597 
135689560 rs12558063 0.00006444 0.01388 0.00001018 
 
Table 3.S10a. All SNPs with a meta-analysis p-value < 1x10-4 for the IBD disease set.  
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CASP, Vitiligo GWAS1 
   Original p-value 
BP SNP meta-analysis p-value Vitiligo GWAS1 CASP 
13539543 rs11797576 0.00007132 0.00001217 0.113 
120356233 rs12852381 0.00003984 2.358x10-07 0.7948 
120361243 rs143231802 0.00005031 1.635x10-07 0.5694 
120363815 rs4271099 0.00002333 1.899x10-07 0.7179 
120363833 rs4335270 0.0000365 4.137x10-07 0.7179 
120364808 rs4480250 0.00003571 4.137x10-07 0.7179 
120372902 rs17258266 0.00004401 3.107x10-07 0.4317 
120377156 rs4300122 0.0000176 5.165x10-07 0.384 
120377239 rs5957593 0.00001991 6.505x10-07 0.3878 
120377928 rs5957594 0.00002138 2.392x10-07 0.4953 
120384209 rs34320000 0.00001928 4.989x10-07 0.3873 
120385628 rs5957596 0.00002515 7.216x10-07 0.3929 
120397795 rs10217856 0.00001654 2.575x10-07 0.4652 
120399965 rs188743539 0.00001312 0.000001017 0.2152 
120402522 rs5956287 0.00005116 0.00000172 0.5429 
120403437 rs12834182 0.00005116 0.00000172 0.5429 
120412794 rs1121546 0.00000699 8.043x10-08 0.4616 
120414055 rs5957620 0.000007265 1.376x10-07 0.408 
120417125 rs9887587 0.000006633 1.304x10-07 0.381 
120422623 rs150986507 0.00001451 1.051x10-07 0.3113 
120423853 rs12839589 0.00001188 3.173x10-07 0.3853 
120428148 rs33977652 0.00004402 0.000001621 0.4982 
120432609 rs138347087 0.00009268 0.000001435 0.4011 
120440791 rs35046609 0.00001107 1.843x10-07 0.423 
120449026 rs60669023 0.000059 0.000001795 0.5376 
120456282 rs16996189 0.00006177 0.000001882 0.5376 
120457727 rs5957651 0.00001094 1.892x10-07 0.4186 
120506286 rs148797601 0.00001516 4.363x10-08 0.3956 
120514199 rs148097246 0.00001568 4.568x10-08 0.3956 
120581955 rs139713212 0.00006601 0.000003853 0.1313 
120615789 rs12387331 0.00006826 0.000005681 0.2252 
120671167 rs111852695 0.00003387 8.647x10-07 0.1378 
120706195 rs140636073 0.00006317 0.000003378 0.1218 
 
Table 3.S10b. All SNPs with a meta-analysis p-value < 1x10-4 for the skin-related disease 
set.  
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Classic Autoimmune (CASP, CIDR celiac disease, WT2 AS, WT2 MS, WT2 UC, WT1 CD, WT1 RA, WT1 T1D) 
      Original p-values 
BP SNP 
meta-analysis 
p-value CASP CIDR AS MS UC CD RA T1D 
135867861 rs6635322 0.00007194 0.1086 0.2043 0.08659 0.06399 0.001849 0.0007687 0.05755 0.3813 
135876353 rs5930994 0.00009651 0.1087 0.1314 0.06854 0.05932 0.003505 0.0003842 0.09112 0.3001 
135879166 rs5930995 0.00005965 0.1093 0.1251 0.06154 0.07357 0.002276 0.0009112 0.03484 0.2871 
135883888 rs5930998 0.00006352 0.1135 0.1161 0.06302 0.07474 0.00133 0.0009793 0.04361 0.2696 
 
Table 3.S10c. All SNPs with a meta-analysis p-value < 1x10-4 for the classic autoimmune disease set 
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Chapter 4 Principal component analysis characterizes shared pathogenetics 
from genome-wide association studies 
(Chang and Keinan 2014) 
 
4.1 Introduction 
 
Comorbidity studies show that some distinct diseases tend to co-occur in the same individuals 
(Sowers 1998; Broadley, Deans et al. 2000; Somers, Thomas et al. 2009; Zaccara 2009; Marrie, 
Horwitz et al. 2011; Sardu, Cocco et al. 2012), pointing to a shared genetic and/or environmental 
component. In the era of genome-wide association studies (GWASs), direct evidence of shared 
genetic risk factors of diseases comes to light (Solovieff, Cotsapas et al. 2013). For example, 
while it has been previously shown that rheumatoid arthritis and type-1 diabetes co-occur 
(Somers, Thomas et al. 2009), GWASs have identified 12 genes associated with both diseases 
(Hakonarson, Grant et al. 2007; !The Wellcome Trust Case Control Consortium 2007; Todd, 
Walker et al. 2007; Barrett, Clayton et al. 2009; Hindorff, Sethupathy et al. 2009; Stahl, 
Raychaudhuri et al. 2010; Festen, Goyette et al. 2011; Okada, Terao et al. 2012; Hindorff, 
MacArthur et al. 2013). More broadly, disease genes obtained from the Online Mendelian 
Inheritance in Man (Hamosh, Scott et al. 2005) were used to assemble the Human Disease 
Network (HDN) (Goh, Cusick et al. 2007; Darabos, Desai et al. 2013), a visual representation of 
genetic similarity between diseases. Pleiotropy of complex diseases and traits has also been 
explored by searching genome-wide for variants implicated in more than one disease (Festen, 
Goyette et al. 2011; Zhernakova, Stahl et al. 2011; Ellinghaus, Ellinghaus et al. 2012). Such 
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studies promise to reveal shared genes and offer an expanded understanding from a genetic 
standpoint of why some diseases tend to co-occur. 
 
Methods for exploring shared genetic risk variants between diseases belong to two main 
categories and have been recently reviewed (Solovieff, Cotsapas et al. 2013). In the first category 
of methods, variants are tested for association to a pair or more of diseases being investigated. In 
one set of methods, a GWAS is carried out on individuals with different diseases pooled together 
( !The Wellcome Trust Case Control Consortium 2007; Festen, Goyette et al. 2011; Zhernakova, 
Stahl et al. 2011; Ellinghaus, Ellinghaus et al. 2012) or by analyzing information for multiple 
diseases available for the same individuals (Lee, Bergen et al. 2011; Hartley, Monti et al. 2012). 
Alternatively, and based only on summary statistics of the association test for each single 
nucleotide polymorphism (SNP), one can simply combine p-values from several GWASs using 
Fisher’s method (Fisher 1925). The CPMA (cross-phenotype meta-analysis) statistic (Cotsapas, 
Voight et al. 2011) is another statistic that tests whether a SNP is associated to more than one 
phenotype. In addition, methods such as the conditional false discovery rate or mixed-models for 
multiple traits have used known pleiotropy between diseases or traits to increase power (Korte, 
Vilhjalmsson et al. 2012; Andreassen, Thompson et al. 2013). Studies employing these methods 
have found shared associations between pairs of diseases such as Crohn’s disease and celiac 
disease (Festen, Goyette et al. 2011), other autoimmune disease pairs (Zhernakova, Stahl et al. 
2011; Ellinghaus, Ellinghaus et al. 2012), bipolar and schizophrenia (Andreassen, Thompson et 
al. 2013) and multiple sclerosis and schizophrenia (Andreassen, Harbo et al. 2014). They have 
additionally shown that SNPs associated with one autoimmune disease are likely to be associated 
to other (though not all) autoimmune phenotypes (Cotsapas, Voight et al. 2011).  
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The second category of methods focuses on using shared variants to learn about the genetic 
similarity between diseases. One method employed by Sirota et al. utilizes the correlation 
between association signals across many SNPs to assess the similarity between pairs of diseases 
and showed that there are likely two distinct autoimmune classes where a risk allele for one class 
may be protective in another (Sirota, Schaub et al. 2009). While another method uses a classifier 
approach to identify diseases that are similar (Schaub, Kaplow et al. 2009). A linear mixed 
model approach can also be applied to assess the shared genetic variation between two diseases 
(Korte, Vilhjalmsson et al. 2012; Lee, Ripke et al. 2013). 
 
These exciting new methods are powerful for studying shared genetic risk variants between 
diseases. At the same time, overcoming some of their limitations can improve the study of shared 
pathogenesis using data from multiple GWASs. First, some methods have focused on analysis of 
individual SNPs. Though this is well suited for scenarios of a single causal SNP in a locus, they 
would lose power when several causal SNPs exist or if different SNPs tag the same underlying 
causal variant, which is especially relevant for diseases with rare causal variants (Wang, Dickson 
et al. 2010; Chang and Keinan 2012) and when the different GWASs are across different 
populations (Marigorta and Navarro 2013) or have used different genotyping arrays. Second, in 
one study where the correlation between association statistics of different studies is used to 
determine shared disease etiology, the correlation statistic weighs all variants equally, whether or 
not they play a role in disease susceptibility (Sirota, Schaub et al. 2009). Third, most methods 
assume as known which diseases share pathogenesis, and while the shared pathogenesis of 
autoimmune disease has been well established (Sirota, Schaub et al. 2009; Cotsapas, Voight et al. 
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2011), it is worthwhile to study shared pathogenesis of other disease classes (Yancik, Havlik et 
al. 1996; McElroy 2004; Zaccara 2009). And fourth, while some approaches perform well for 
two correlated traits or diseases, extending the analysis to more than two traits can become 
difficult (Korte, Vilhjalmsson et al. 2012).   
 
In this study, we present a novel method, disPCA, which uses principal component analysis 
(PCA) to learn about the shared genetic risk of distinct diseases. PCA maps data from the 
original axes into new axes in principal component (PC) space via a stretch and rotation of the 
original axes. Each new axis or PC captures the maximal level of variation in the data not 
captured by previous PCs. Thus, each PC can potentially tell a different, orthogonal story 
regarding the data. Our method is based on summary level statistics from GWASs of different 
diseases. We combine data from individual SNPs into gene-based statistics via several p-value 
combination methods. PCA is applied to a matrix across genes and GWAS datasets, with entries 
representing the strength of association (p-value) between a gene and the disease studied in a 
dataset. This method is gene-centric, with the PCA weighing genes by their role in differentiating 
between different GWAS, and can be applied to study multiple diseases without prior knowledge 
of their shared pathogenesis, thereby overcoming all the limitations of existing methods outlined 
above. disPCA also accounts for potential confounders due to methodological differences 
between studies, such as in genotyping array, which can otherwise lead to these differences being 
captured by the PCA.  
 
Equipped with this novel method and with data from 31 GWAS datasets, we considered the level 
of shared pathogenesis between diseases and classes of diseases from all genes, which we term 
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shared pathogenetics. Diseases with more similar underlying genetics are more likely to be 
located closer together in PC space. As PCA is a non-parametric method, it makes no 
assumptions regarding which diseases are more similar and does not aim to model it, thereby 
allowing discovery of new relationships between diseases by examining the top PCs. Each PC is 
a linear combination of genes, with the leading PCs expected to give more weight to genes that 
distinguish well between diseases. Diseases with no separation along any PC indicate that they 
tend to share the pathogenetics underlying that PC. By studying the set of genes underlying a PC 
for enrichment in specific pathways, we can further assess the function and relationship of genes 
that separate different disease clusters in PC space. 
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4.2 Materials and Methods 
4.2.1 disPCA  
 
We developed a method, disPCA, for studying the relationship between diseases based on their 
level of disease risk genes shared. The method works on the gene-level by first combining 
information from all SNPs in and around each gene. Considering gene-level statistics 
compensates for different tag SNPs being associated in different datasets even in cases where 
they capture the same causal variant. It also aggregates information across multiple tag SNPs in 
each dataset, as well as allows for different underlying causal variants in the same gene being 
associated with the risk of different diseases. To be widely applicable, disPCA is based solely on 
the p-values of association of each SNP with the disease under study. Importantly, all SNPs and 
consequently all genes are considered, rather than focusing on genes that meet a genome-wide 
significance level of association with a disease. We apply PCA to many different GWASs to 
axiomatically find and assign importance to genes based on their contribution to distinguishing 
between diseases and disease classes. The ensuing distance between different disease datasets in 
PC space inversely corresponds to their level of shared pathogenetics. 
 
4.2.2 Gene-level significance levels  
 
For each protein-coding gene from the HGNC database (Gray, Daugherty et al. 2013), we 
mapped all SNPs that are in the gene or within 0.01cM from it (genetic distances were 
determined via the Oxford genetic map based on HapMap2 data (Myers, Bottolo et al. 2005; 
Frazer, Ballinger et al. 2007)). We discarded all SNPs that were not mapped to within 0.01cM of 
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any gene. If a SNP lay between two genes, it was assigned to the closer gene. For each GWAS 
dataset, we determined the significance of association of each gene with the assayed disease 
using the following simulation procedure. Let the observed p-value of a gene be the minimum p-
value of the n SNPs mapped to the gene. We compared the observed p-value to that of 100,000 
groups of n consecutive SNPs chosen in random. Based on these groups, we assign a new p-
value to each gene as the proportion of groups for which the observed minimum p-value for that 
gene is less significant than that of the group. This random sampling procedure may be biased in 
regions of high linkage disequilibrium (LD) when mapping SNPs to genes using genetic distance 
(e.g. consecutive SNPs in regions of high LD will be more correlated than those in regions of 
lower LD). However, for any given gene, these will equally affect each of the datasets. To 
validate this, we also applied disPCA to p-values obtained from mapping SNPs to genes using 
physical distance: a SNP was mapped to a gene if it was in the gene or within 10kb of it. 
Comparing these results to results based on mapping via genetic coordinates revealed the same 
clustering of diseases (Figure 4.S1). Furthermore, average loading of genes with the top 50 
loadings on the first two PCs were significantly correlated (r>0.67, p-value < 8.4x10-8, Table 
4.S1). Thus, in the main text we present results based on mapping by genetic distance as 
described above. 
 
To consider information from beyond only the most significant SNP in a gene, we also 
implemented truncated tail strength (Jiang, Zhang et al. 2011) and truncated product (Zaykin, 
Zhivotovsky et al. 2002) to combine p-values in each gene in replacement of the minimum p-
value, and followed a similar procedure for assigning new gene-level p-values. For the analyses 
presented in the following, results from all methods were similar though results with the 
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minimum p-value approach clusters similar diseases better (Figure 4.S2-S3). We thus only report 
in the main text results from the minimum p-value approach. Code to carry out this procedure is 
publicly available at http://keinanlab.cb.bscb.cornell.edu/content/tools-data. 
 
4.2.3 PCA implementation and confounders 
Assume a matrix Z, a d x g matrix of the –log10 gene-level p-values, where d is the number of 
GWAS datasets, and g is the number of genes present in all datasets. We center the matrix by 
subtracting the column means from each column. Thus the centered matrix B has entries: 
  (1)
 
To obtain the PCs of matrix B, we must find the eigenvectors and eigenvalues of its covariance 
matrix BBT. Let vi be a vector of length d and let  be a scalar. vi is the eigenvector and  the 
eigenvalue of BBT if the following is satisfied: 
   (2) 
The principal components of B are the normalized eigenvectors of its covariance matrix, BBT, 
where the eigenvectors are ordered such that the largest eigenvalue corresponds to the first 
principal component. Each eigenvector is additionally orthogonal to all other eigenvectors. Thus, 
from (2), we can decompose BBT as follows: 
  (3) 
Where the columns of U contain the principal components and " is a diagonal matrix with 
entries equal to the eigenvalues of B’s covariance matrix. One can similarly construct the 
singular value decomposition (SVD) of B. The SVD of B can be written as: 
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  (4) 
where V is a d x d matrix, D is a d x g diagonal matrix, and W is a g x g matrix. V and W contain 
the left and right singular vectors of B, respectively, and D contains the singular values of B in its 
diagonal. Substituting equation (4) for B in equation (3), we find that  
  (5) 
Thus, the principal components of B, the eigenvectors of its covariance matrix, are equivalent to 
the left singular vectors of B. In addition, the eigenvalues of B are equivalent to the square of its 
singular values.  
 
We applied SVD to the matrix B using the R (R Core Team 2013) implementation of PCA/SVD 
(prcomp), with no scaling of the data. Due to the heterogeneity of the GWAS datasets (Table 
4.S2), variation uncovered by PCA can also reflect differences in features such as genotyping 
array, association method, and sample size, rather than underlying disease risk genes. To ensure 
that these features did not influence our results, we first tested each gene for association with 
each of these features. Let zi=Zi,! be the vector corresponding to the association statistic for gene 
i across the d datasets. We considered a linear regression of zi as a function of the covariates: 
, where C1, C2, C3 are vectors of length d that represent the 
genotyping array, association method and the log10 of the sample size respectively, in each of the 
studies (Table 4.S2). Testing the significance of regression coefficients can reveal genes that are 
associated with any of these potential confounders. In our following analysis, 19 genes were 
significantly associated with association method. However, genes not significantly associated to 
the above confounders may similarly have an effect. Hence, we also applied SVD (as described 
above) to the residualized matrix, namely matrix R with rows
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. We found that applying SVD to R results in the top PCs 
capturing a higher fraction of the variance of the data than when applied to the original matrix Z, 
though results are qualitatively similar between the two. We thus present results derived from the 
residualized matrix R. Resulting distances between datasets were assessed visually by plotting 
datasets in PC space. To quantify the clustering of datasets, we additionally applied hierarchical 
clustering in R (R Core Team 2013) (hclust) to the Euclidean distance between pairs of datasets 
across the first two PCs. 
 
4.2.4 Simulation study 
We simulated a matrix Z for two disease classes, each with 5 diseases (A1,A2,A-
3,A4,A5,B1,B2,B3,B4,B5) and 10,000 genes. In general, under the null hypothesis of a region 
containing no risk variant and assuming no confounding factors (e.g. population stratification), 
p-values should be uniformly distributed between 0 and 1. On the other hand, associated risk 
variants should be enriched for smaller p-values. We thus considered three sets of genes. The p-
values for the first set of genes was drawn from the U(0,1) distribution for all diseases, thus no 
pleiotropy was captured in this set of genes. The second set of genes was distributed U(0,0.05) 
for the first disease class (A1,…,A5) and distributed U(0,1) for the second disease class (B1,…,B5). 
Finally the third set of genes was distributed U(0,0.05) for the following diseases: A1, A2, B1, B2 
and distributed U(0,1) for all other diseases. Thus the second set of genes simulates pleiotropy 
between diseases in disease class A, while the last set of genes simulates pleiotropy between 
diseases in both disease classes.  
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4.2.5 Disease and pathway enrichment analysis 
Disease enrichment analysis was completed using the online tool WebGestalt (Zhang, Kirov et 
al. 2005; Wang, Duncan et al. 2013) to query the PharmGKB (Whirl-Carrillo, McDonagh et al. 
2012) database. WebGestalt tests for enrichment of a category of genes in the observed set of 
genes using the hypergeometric test (Zhang, Kirov et al. 2005). Bonferroni correction for 
multiple tests was applied and all reported p-values are following this correction. We restricted 
analysis to categories that contained a minimum of 5 genes in our analysis with the largest 50 
weightings in the top two PCs. For gene categories with overlapping or the same set of genes, we 
list the most significant category. To reduce biases introduced by the clustering of genes with 
similar function, we filtered our list of genes with the top 50 loadings on the top two PCs by 
removing the latter gene out of a pair of genes within 0.1cM of each other. We then applied 
WebGestalt to this filtered subset of genes. 
 
Pathway enrichment analysis was completed using the Gene Set Enrichment Analysis (GSEA) 
tool (Subramanian, Tamayo et al. 2005). GSEA sorts genes according to a score, which here is 
the weighting of a gene in the PC under study. It then assesses whether genes belonging to a 
certain category (e.g. pathway) are non-randomly distributed in the sorted list. As input to 
GSEA, we utilized the weights of genes in the top two PCs. GSEA carried out 10,000 gene-set 
permutations to determine FDR (false discovery rate) q-values. We queried the BioCarta and 
KEGG pathway databases. We restricted analysis to categories that contained a minimum of 5 
genes in our analysis. Throughout we present enrichment analysis only for the top two PCs, 
though other PCs are available and can be assayed for further insight into the diseases studied. 
As above, to reduce biases introduced by the clustering of genes with similar function, we 
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filtered our full list of genes by removing the latter gene out of a pair of genes within 0.1cM of 
each other and reanalyzed this subset of genes (n=5,298) with GSEA.  
 
4.2.6 Testing for non-random distribution of p-values 
We followed a similar approach to that implemented in Zhernakova et al. 2011 (Zhernakova, 
Stahl et al. 2011) while applying it to genes instead of individual SNPs to test for non-random 
distribution of association values. For each disease pair we retained all k genes that were 
nominally significant in one disease (p-value < 0.01). We then tested the null hypothesis of a 
uniform distribution of p-values in the second disease using Fisher’s method for combining p-
values: , where pi is the p-value for association of gene i in the second disease. 
Nearby genes in linkage disequilibrium may violate the independency assumption in Fisher’s 
method. We thus performed a separate analysis after removing the latter of the two genes that 
were within 0.1cM of each other and nominally significant in one disease.  
 
4.2.7 Application of disPCA to 31 GWAS datasets 
We analyzed a total of 31 GWAS datasets (Helms, Cao et al. 2003; Karamohamed, Golbe et al. 
2005; Nichols, Pankratz et al. 2005; Duerr, Taylor et al. 2006; Nair, Stuart et al. 2006; Suarez, 
Duan et al. 2006; Hunter, Kraft et al. 2007; Matarin, Brown et al. 2007; Saxena, Voight et al. 
2007; Scott, Mohlke et al. 2007; Scuteri, Sanna et al. 2007; !The Wellcome Trust Case Control 
Consortium 2007; Boomsma, Willemsen et al. 2008; Cronin, Berger et al. 2008; Harley, 
Alarcon-Riquelme et al. 2008; Hom, Graham et al. 2008; Li, Wetten et al. 2008; Baranzini, 
Wang et al. 2009; Barrett, Lee et al. 2009; Nair, Duffin et al. 2009; Sabatti, Service et al. 2009; 
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Heinzen, Need et al. 2010; Jin, Birlea et al. 2010; Laaksovirta, Peuralinna et al. 2010; Neale, 
Medland et al. 2010; Remmers, Cosan et al. 2010; Evans, Spencer et al. 2011; Sawcer, 
Hellenthal et al. 2011; Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) 
Consortium 2011; Ahn, Ding et al. 2012; Jin, Birlea et al. 2012) that spanned different types of 
cancers, autoimmune diseases, neurological disorders, psychiatric disorders, type-2 diabetes 
(T2D), ischemic stroke and body mass index (BMI) (Table 4.S2). Datasets were publicly 
available, obtained from dbGaP or obtained via collaborations. These datasets had non-
overlapping samples and were of European ancestry only. For Wellcome Trust Case Control 
(WT) related datasets, we distributed controls between the five datasets such that none had 
overlapping samples. For WT type-1 diabetes, rheumatoid arthritis and Crohn’s disease, we 
obtained further controls from the WT hypertension, cardiovascular disease and bipolar case data 
( !The Wellcome Trust Case Control Consortium 2007). After obtaining gene-level association 
statistics for 14,018-17,438 autosomal genes for each dataset, we limited our analysis to the 
11,927 genes that overlapped all studies. Nineteen of these genes were significantly associated 
with association method after multiple-testing correction (see above).  
 
4.2.8 Replication of disPCA 
We tested the replicability of disPCA when applied to real GWASs using six datasets for which 
we had access to the original data (Duerr, Taylor et al. 2006; !The Wellcome Trust Case Control 
Consortium 2007; Baranzini, Wang et al. 2009; Jin, Birlea et al. 2010; Sawcer, Hellenthal et al. 
2011; Jin, Birlea et al. 2012). Each dataset was split into independent subsets of equal size (+/- 
two samples). We then used PLINK’s logistic regression (Purcell, Neale et al. 2007) to evaluate 
association of each SNP to disease risk. We additionally incorporated covariates derived from 
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EIGENSOFT into the regression analysis (Patterson, Price et al. 2006) to control for population 
structure. We randomly chose one subset of each of the six datasets for one disPCA analysis, and 
the rest for another. Hence, these two analyses consist of independent samples. 
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4.3 Results 
We first applied disPCA to a simulated dataset (Materials and Methods). We varied the number 
of genes belonging to each category, thereby varying how much power there was to detect 
pleiotropy between the simulated diseases. disPCA was unable to clearly cluster pleiotropic 
diseases when diseases shared fewer than 40 genes that had p-values below 0.05 (Figure 4.1a-b, 
4.S4-4.S6). This can be seen both visually via PCA plots, and via hierarchical clustering based 
on the Euclidean distance between datasets in the presented space of the first two principal 
components (PCs) (Figure 4.1, 4.S4-4.S6). When diseases are indeed clustered by their simulated 
pleiotropy according to disPCA (Figure 4.1b), the first two PCs explain a similar fraction of the 
variance (Figure 4.1c), which may increase or decrease depending on the number of genes 
contributing to pleiotropy (Figure 4.S7). Genes with p-values < 0.05 (Materials and Methods), 
which contribute to the simulated pleiotropy between diseases, are also enriched for larger 
loadings (Figure 4.1d-e).  
 
We next applied disPCA to diseases for which we had two datasets. We utilized autoimmune 
diseases (for which we had the most pairs of datasets) and a pair of schizophrenia datasets (as 
schizophrenia has a high heritability (Kendler and Diehl 1993)). We observed that datasets of the 
same diseases were generally clustered together (Figure 4.2-4.3). We additionally observed that 
Crohn’s disease is separated from other autoimmune diseases. This result is consistent with 
previous reports that inflammatory bowel disorders (IBDs) are distinct from other autoimmune 
disorders (Sirota, Schaub et al. 2009). As in the simulated scenarios, the variance explained by 
each PC was similar and suggests that less than a hundred genes contribute to the similarity 
between each dataset.  
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To test the replicability of the results, we further divided each of the six datasets, for which we 
had the raw data, into two subsets consisting of the same or similar samples of cases and controls 
(Materials and Methods). We then performed two disPCA analyses, one on a randomly chosen 
subset of each of the six datasets and another on the remaining subsets. We found that both 
independent sets produced the same clustering of diseases (Figure 4.S8-4.S9). Loadings for 50 
genes with the largest average loading of PC1 and PC2 in each set were also significantly 
correlated across the replication sets (r>0.44, p-value < 1.2x10-3, Table 4.S3).  
 
We applied disPCA to a final set of 31 datasets, including autoimmune diseases, cancers, obesity 
related diseases and traits, psychiatric disorders and neurological disorders. As before, the top 
PCs explain a similar portion of the variance, with the first two PCs capturing interpretable 
separation of diseases. PC1 splits systemic lupus erythematosus (SLE), celiac disease and one 
schizophrenia dataset from all other diseases (Figure 4.4). Alternatively, PC2 splits autoimmune 
diseases from other diseases, and within autoimmune diseases, inflammatory bowel disorders are 
clustered together (Figure 4.5). Schizophrenia, major depressive disorder, cancers, T2D and 
neurological disorders lie on the negative end of PC2, while attention deficit hyperactivity 
disorder (ADHD) and some autoimmune diseases lie near the origin.  
 
As disPCA teases out the important genes of shared and distinct pathogenetics across disease 
datasets, we next investigated which genes strongly contribute to each PC. The result of applying 
PCA on a matrix of association values (Materials and Methods) is that each resulting PC is 
simply a linear combination of genes, whereby each gene is assigned a weight for its contribution 
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to that PC. We retrieved the genes with the top 50 absolute weights for each of the top two PCs 
underlying Figure 4.4 and tested their disease enrichment (Materials and Methods). The top 
genes underlying the first PC were significantly enriched for genes associated with lupus and 
autoimmune related diseases, while genes underlying the second PC were mostly enriched for 
association to IBD (Table 4.1). These enrichment results are consistent with the separation of 
studies across each of these 2 PCs with PC1 separating studies of SLE and other autoimmune 
diseases, and PC2 separating studies of IBD from other diseases. The results were largely 
unchanged even after filtering genes that were within 0.1cM of each other (Table 4.1) (Materials 
and Methods).  
 
Though the results of the disease enrichment analysis support that disPCA extracts biologically 
relevant signals, the arbitrary cutoff of the 50 top genes goes against the potential of PCs being 
linear combinations of all genes. We thus used GSEA (Subramanian, Tamayo et al. 2005), which 
supports analyzing a pre-ranked list of all genes, to perform pathway enrichment of each PC. 
GSEA assesses whether genes belonging to a certain pathway are non-randomly distributed in 
the list of pre-ranked genes. We ranked all genes by the weight in the PC under study. Results of 
this pathway analysis revealed enrichment for immune related pathways on the first 2 PCs (Table 
4.2) at an FDR of 0.25, as suggested by GSEA (Subramanian, Tamayo et al. 2005) (GSEA 
manual online), though this entails that 1 in 4 of our results are false positives on average. The 
top two pathways enriched on PC1 were the antigen processing and presentation and the 
intestinal immune network IgA production pathways, which are crucial immune-related 
pathways. In particular, intestinal IgA antibodies may have a role in inflammatory bowel disease 
(Macpherson, Khoo et al. 1996; Bouvet and Fischetti 1999) and celiac disease (Cunningham-
 
 
 
 
107 
Rundles 2001). On PC2, the most significant pathway was the NOD-like receptor signaling 
pathway. NOD-like receptors have been associated to CD, while other immune-related genes 
likely interacting with NOD2 have been associated to UC (Rubino, Selvanantham et al. 2012).  
Overall, a majority of the pathways are related to the immune systems. For example, the Fc 
epsilon RI signaling pathway is related to the antibody IgE, which induces inflammatory 
response (Pearlman 1999). Other pathways are related to neurons (i.e. the neurotrophin signaling 
pathway and the Trk-A pathway). In particular, the neurotrophic factor BDNF (brain-derived 
neurotrophic factor), which is a part of the neurotrophin pathway, has been previously associated 
to Alzheimer’s, Parkinson’s disease and depression (Momose, Murata et al. 2002; Ventriglia, 
Bocchio Chiavetto et al. 2002; Sen, Nesse et al. 2003). More recently, an intronic variant in this 
gene has also been associated to BMI (Berndt, Gustafsson et al. 2013). These associations may 
explain the separation of neurological, psychiatric and BMI studies on PC2. Because similar 
genes are sometimes also physically located closer together, we reran GSEA after filtering genes 
that were within 0.1cM of each other (Materials and Methods). The top two pathways on the first 
PC remained significant, while only the top pathway in PC2 remained significant (Table 4.S4).  
 
Many autoimmune diseases share associations from the HLA region. We thus reran disPCA after 
removing all genes in and around the HLA region, and found a slightly different visual PCA map 
(Figure 4.6). SLE and celiac disease were no longer distinguished from other autoimmune 
diseases and instead lay near the origin. PC1 now differentiated IBD from other diseases, and 
PC2 distinguished vitiligo from schizophrenia. This was further supported by clustering results 
on the first two PCs (Figure 4.S10). A GSEA analysis of the PC loadings retained the NOD-like 
receptor signaling pathway on PC1 instead of PC2 (Table 4.3). Analysis of PC2 loadings 
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revealed additional immune related pathways that were not enriched in our previous analysis 
including the HLA region.  
 
Our findings that PC1 splits some autoimmune diseases, and a schizophrenia study from studies 
of other diseases prompted us to further explore the shared pathogenetics between diseases by 
testing for the non-random distribution of gene-based p-values in one disease based on their 
nominal significance in another disease (Materials and Methods). Generally, association statistics 
are non-randomly distributed when considering most pairs of autoimmune diseases, i.e. testing 
for non-random distribution in one autoimmune disease dataset based on significance in another 
autoimmune disease dataset (Figure 4.7). As a control, we tested for non-random distribution for 
a random set of genes and found that no disease pair was significant for non-random distribution 
(Figure 4.S11). Our results reported a similar story as observed via disPCA. Genes nominally 
significant in rheumatoid arthritis, type-1 diabetes and ankyolosing spondylitis were non-
randomly distributed in SLE and vice versa. We also found that genes nominally significant for 
one schizophrenia study were non-randomly distributed in a number of autoimmune diseases 
(Figure 4.7). These signals remained even after genes within 0.1cM of another gene were 
removed (Figure 4.S12) (Materials and Methods).  
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4.4 Discussion 
In this study we introduced a new method, disPCA, to explore the shared pathogenetics of 
various diseases and disease classes based on GWAS data. PCA has been widely used in 
population and medical genetics. Applied to genome-wide genotyping data, it can recapitulate 
European geography (Novembre, Johnson et al. 2008), has been used as a tool to assess and 
correct for population stratification in GWAS (Patterson, Price et al. 2006; Price, Patterson et al. 
2006) and has also been proposed as a tool for reducing the dimensionality of multiple 
phenotypes for association analysis (Klei, Luca et al. 2008). Our disPCA method considers PCA 
on a different type of matrix, whereby different GWASs are studied in the space of all genes. It 
can group GWASs of different diseases together based on gene-level association statistics, while 
accounting for biases due to heterogeneity in sample size, association method, genotyping array 
and other confounders between studies. This implementation of PCA weighs genes differently on 
each PC in a manner that distinguishes between diseases. Hence, the higher the level of shared 
pathogenetics between diseases, the closer they will be in PC space. This is in contrast to a 
previous method that weights all SNPs equally (Sirota, Schaub et al. 2009). In general, a 
correlation-based method is less powerful since the correlation between studies across all genes 
is low, even when the same disease is studied. For example, the correlation coefficient between 
the –log10 p-values of the two CD studies is 0.048, and it is 0.063 and 0.031 between ulcerative 
colitis and each of the two CD studies. Furthermore, the highest correlation between pairs of 
datasets was obtained for schizophrenia (0.13, p-value=2.2x10-16) while the lowest was obtained 
for type-2 diabetes (0.0031, p-value=0.73). These results show that there is less power when 
aggregating information across all genes and that disPCA is able to tease out and weigh the 
suitable set of genes underlying shared pathogenetics. 
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Though disPCA is designed to uncover shared disease etiology between diseases, other sources 
of correlation between datasets can also contribute to disPCA. Potential confounders include 
population structure, shared samples between datasets and technical artifacts. To minimize the 
impact of these confounders disPCA was only applied to studies of individuals with European 
ancestry and datasets that had no overlapping case or control data. We additionally accounted for 
technical artifacts introduced by the genotyping array, association method and sample size by 
regressing out variation in the data attributed to these sources (Materials and Methods). Though 
we cannot account for other potential confounders that are unknown, the remaining correlation 
between studies is likely to be due to a shared disease etiology. 
 
We applied disPCA to data from 31 GWAS that cover a range of diseases in four main classes: 
autoimmune diseases, cancers, neurological disorders and psychiatric disorders. We additionally 
analyzed GWASs on T2D, BMI and ischemic stroke. We first observed that different studies of 
the same diseases tend to lie closer together on the lead PCs (Figure 4.2). This is in support of 
studies of the same disease replicating many of the same signals of associations when samples 
are of similar ancestry. We additionally find that disPCA positions diseases within the same class 
closer together (Figure 4.4). This was especially the case for the major types of IBDs (i.e. 
Crohn’s disease and ulcerative colitis), which clustered close together (Figure 4.5). Between the 
different disease classes, disPCA found overlap between non-autoimmune diseases and traits, 
and suggests a connection between schizophrenia and some autoimmune diseases.   
 
Using the weightings of genes on each of the leading PCs, we performed disease and pathway 
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enrichment analysis. We found that PC1, which mainly splits autoimmune disorders from each 
other, is significantly enriched for genes associated to immune and autoimmune disorders. PC2, 
which splits IBD studies from studies of other diseases, is significantly enriched for genes in 
some inflammatory related pathways and genes associated with IBD. Furthermore, some neuron-
related pathways were associated to loadings on PC2. In particular, abnormal neurotrophins 
levels in the brain have been associated to schizophrenia (Durany, Michel et al. 2001; Buckley, 
Mahadik et al. 2007). Excluding the HLA region revealed significant enrichment for genes in 
other immune-related pathways. Though the specific analysis presented in this paper focused on 
the top two PCs, further PCs estimated by disPCA can be examined. For example, PC4 of 
disPCA on all GWASs distinguishes rheumatoid arthritis from other diseases (Figure 4.S13). 
Pathway enrichment analysis highlighted the calcineurin pathway (FDR = 0.182), which 
involves t-cell activation. Additionally, though schizophrenia and vitiligo datasets are further 
apart on the first two PCs, each pair of datasets is clustered closer together on PC3 and PC4. 
Altogether these results support the validity of the enrichment analysis based on disPCA. The 
analysis in turn also raises new hypotheses of disease etiology by pointing to additional pathways 
and enrichment for other diseases that were not previously observed. 
 
Prompted by the results of disPCA, we further explored shared pathogenetics by testing for the 
non-random distribution of association statistics between pairs of disease studies (Figure 4.7). 
Autoimmune diseases show non-random distribution of association statistics with one another. 
Interestingly, genes nominally associated with one of the schizophrenia studies were non-
randomly distributed in studies of several autoimmune diseases (i.e. ankyolosing spondylitis, 
systemic lupus erythematosus, and T1D). This supports our disPCA results above and is in 
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agreement with epidemiological evidence for a relationship between autoimmune diseases and 
schizophrenia (Benros, Eaton et al. 2013). This relationship was not observed in the other 
schizophrenia study, which may be due to a number of factors such as a lack of power. Though, 
if indeed autoimmune diseases and schizophrenia share disease etiology, then just as one would 
not include individuals with ulcerative colitis as controls for a Crohn’s disease GWAS since they 
both are IBDs, one should also be wary of including individuals with schizophrenia as controls in 
an autoimmune GWAS (and vice versa) as doing so may decrease power in loci implicated in 
both diseases.  
 
Finally, we make a few recommendations for future applications of disPCA to additional studies: 
(1) Biases can be introduced when studies share sample data; (2) As disPCA maximizes variance 
across diseases, genes that are implicated in all analyzed diseases will not contribute to the lead 
PC as they do not distinguish diseases from each other; (3) While here we only focused on using 
the strength of association and on gene-level signals, the method itself is highly flexible. One can 
further utilize the direction of association (protective versus deleterious), the heritability at each 
locus (Gusev, Bhatia et al. 2013), an analysis at the pathway-level or in linkage-disequilibrium 
blocks, and/or include other non-genic functional elements; (4) disPCA can be used to generate 
new hypotheses, which can then be tested by conducting more focused association studies in 
independent data or by using its output to better combine different diseases in an independent 
meta-analysis. In conclusion, disPCA offers users a unique general overview of the disease 
landscape by studying their distinct and shared pathogenetics and flagging pathways and genes 
for further investigation. disPCA’s flexibility and computational efficiency proves itself as an 
excellent tool to be applied to additional diseases and disease classes to further our knowledge of 
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shared pathogenetics.  
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4.5 Figures 
 
Figure 4.1. disPCA of ten simulated diseases.  
The p-values for ten diseases were simulated for 10,000 genes (Materials and Methods). Class A 
diseases had p-values uniformly distributed between 0 and 0.05 for 40 genes, while two diseases 
from class A (A_1, A_2) and two diseases from class B (B_1, B_2) had p-values similarly 
distributed for a separate 40 genes (Materials and Methods). All other diseases had p-values that 
were randomly distributed between 0 and 1. A) The simulated data is displayed on PC1 and PC2. 
PC1 separates (A_1, A_2, B_1, B_2) from all other diseases, while PC2 separates class A diseases 
from class B diseases. B) Dendrogram derived from a clustering analysis based on the Euclidean 
distance between datasets in the space of the first two PCs (represented as the height of the 
branches). C) PC1 and PC2 account for a similar amount of variance. D) Loadings for each gene 
are displayed sequentially for PC1. The 40 genes contributing to pleiotropy between the two 
diseases in each class are enriched for larger absolute loadings. E) Similar to (D), with loadings 
for PC2 displayed. The 40 genes contributing to correlation between diseases in each class and 
are also enriched for larger loadings.  
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Figure 4.2. disPCA of datasets of the same disease. 
A) Pairs of datasets of the same autoimmune diseases and schizophrenia are displayed on PC1 
and PC2. Dataset labels are indicated in the form of disease-type_ study-name. The size of points 
is proportional to the sample size of the original study (Table 4.S2). Diseases include systemic 
lupus erythematosus (SLE), vitiligo (Vit), multiple sclerosis (MS), schizophrenia (Schizo) and 
Crohn’s disease (CD). Datasets of the same diseases tend to lie closer together on PC1 and PC2. 
B) The portion of variance explained by each PC is displayed. Three additional PCs explain 0% 
of the variance corresponding to the number of confounders we accounted for (Materials and 
Methods). C) The weightings for genes on PC1 are displayed and ordered according to their 
weights. D) Similar to (C) where loadings are for PC2.  
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Figure 4.3. Dendrogram of datasets of the same disease.  
Hierarchical clustering was applied to the Euclidean distance between datasets in the first two 
PCs presented in Figure 4.2 (Materials and Methods). The height of the branches represents the 
Euclidean distance between datasets in the space of the first two PCs. Datasets of the same 
diseases are clustered together.    
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Figure 4.4. disPCA of all diseases and traits.  
A) Autoimmune diseases (purple), cancers (pink), psychiatric disorders (yellow), neurological 
disorders (green), and other diseases and traits (grey) are shown on PC1 and PC2. PC1 accounts 
for 4.48% of the variance, while PC2 accounts for 4.21%. Additional diseases include 
Alzheimer’s disease (Alz), amyotrophic lateral sclerosis (ALS), ankyolosing spondylitis (AS), 
attention deficit hyperactivity disorder (ADHD), Behcet’s disease (Behcets), body mass index 
(BMI), breast cancer (BreastC), celiac disease (CeliacD), ischemic stroke (IscStroke), major 
depression (MajDep), Parkinson’s disease (Parkin), prostate cancer (ProstateC), psoriasis (Psor), 
rheumatoid arthritis (RA), type-1 diabetes (T1D), type-2 diabetes (T2D), ulcerative colitis (UC). 
PC1 clusters celiac disease and SLE together, while PC2 separates inflammatory bowel diseases 
from other diseases and traits. B) The portion of variance explained by each PC is displayed. 
Three additional PCs explain 0% of the variance corresponding to the number of confounders we 
accounted for (Materials and Methods). C) The weightings for genes on PC1 are displayed and 
ordered according to their weights. D) Similar to (C) where loadings are for PC2. 
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Figure 4.5. Dendrogram of datasets of all diseases and traits.  
Dendrogram derived from hierarchical clustering analysis applied to distance (in PC space) 
between datasets presented in Figure 4.4. Inflammatory bowel diseases are clustered together, in 
addition to SLE and celiac disease. 
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Figure 4.6. disPCA of all diseases and traits excluding the HLA and surrounding region.  
A) Similar to Figure 4.4 where genes in the HLA and surrounding region (Materials and 
Methods) were removed. Though IBD remains separated as in the original disPCA, the clustering 
of T1D and SLE is no longer captured by the top two PC’s. B) The portion of variance explained 
by each PC is displayed. C) The weightings for genes on PC1 are displayed and ordered 
according to their weights. D) Similar to (C) where loadings are for PC2.  
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Figure 4.7. Non-random distribution of genes for all analyzed datasets from Figure 4.  
Genes nominally significant for diseases on the y-axis were tested for non-random distribution in 
diseases on the x-axis (Materials and Methods), with –log10 presented on the color scale on the 
right. White entries denote p-values < 1x10-17. The most significant results are for pairs of 
similar diseases and between pairs of autoimmune diseases. In addition, pairs between some 
autoimmune diseases and schizophrenia also display significant results.  
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Figure 4.S1. Dendrogram derived from clustering analysis of datasets of the same diseases 
using physical distance mapping.  
SNPs were mapped to genes if they were within 10kb of the gene. Clustering analysis of 
resulting disPCA revealed the same clusters as disPCA with genetic coordinates (Figure 4.3).  
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Figure 4.S2. Dendrogram of clustering analysis of datasets of the same diseases with the 
truncated product method.  
Similar to Figure 4.3, with the truncated product method used to combine SNP p-values per 
gene.  
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Figure 4.S3. Dendrogram of clustering analysis of datasets of the same diseases with 
truncated tail strength method.  
Similar to Figure 4.3, with the truncated tail strength method used to combine SNP p-values per 
gene. 
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Figure 4.S4. Simulated diseases with ten nominally significant genes.  
A) Similar to Figure 4.1 in main text with only ten nominally significant genes for each set of 
pleiotropic diseases (Materials and Methods). Clustering of the diseases sets is not observed. B) 
Dendrogram derived from clustering analysis as similarly presented in Figure 4.1b. C) The 
portion of variance explained by each PC is displayed. D-E) The loadings for PC1 and PC2 are 
displayed after sorting genes according to their loadings. 
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Figure 4.S5. Simulated diseases with twenty nominally significant genes.  
A) Similar to Figure 4.1 with twenty nominally significant genes for each set of pleiotropic 
diseases. As in Figure 4.S2, diseases are not clustering according to the sets though nominally 
significant genes are enriched for larger absolute loadings (Materials and Methods). B) 
Dendrogram derived from clustering analysis as similarly presented in Figure 4.1b. C) The 
portion of variance explained by each PC is displayed. D-E) The loadings for PC1 and PC2 are 
displayed after sorting genes according to their loadings. 
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Figure 4.S6. Simulated diseases with thirty nominally significant genes.  
A) Similar to Figure 4.1 with thirty nominally significant genes for each set of pleiotropic 
diseases. The proper clustering of diseases is beginning to emerge. B) Dendrogram derived 
clustering analysis as similarly presented in Figure 4.1b. C) The portion of variance explained by 
each PC is displayed. D-E) The loadings for PC1 and PC2 are displayed after sorting genes 
according to their loadings. Genes with nominally significant p-values are enriched for larger 
absolute loadings. 
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Figure 4.S7. Simulated diseases with 100 and 200 nominally significant genes.  
A) Similar to Figure 4.1 with 100 and 200 nominally significant genes for the two sets of 
pleiotropic diseases. Disease sets are tightly clustered and the first two PCs explain a larger 
portion of the variance compared to other PCs. B) Dendrogram derived from clustering analysis 
as similarly presented in Figure 4.1b. C) The portion of variance explained by each PC is 
displayed. D-E) The loadings for PC1 and PC2 are displayed after sorting genes according to 
their loadings.  
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Figure 4.S8. Dendrogram of clustering analysis of Replication Set 1 datasets.  
Clustering of the distance in PC space between datasets in Replication Set 1. Diseases include 
vitiligo (Vit), multiple sclerosis (MS), schizophrenia (Schizo) and Crohn’s disease (CD). 
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Figure 4.S9. Dendrogram of clustering analysis of Replication Set 2 datasets.  
Similar to Figure 4.S8 with datasets from Replication Set 2.   
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Figure 4.S10. Dendrogram of clustering analysis of all diseases and traits excluding the 
HLA and surrounding regions.  
Figure is similar to Figure 4.5, with clustering analysis of distance between datasets based on the 
disPCA between all diseases and traits presented in Table 4.S2 after removing the HLA and 
surrounding regions. 
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Figure 4.S11. Non-random distribution of randomly chosen genes.  
A random subset of genes were chosen to be tested for non-random distribution in diseases on 
the x-axis, with –log10 presented on the color scale on the right. White entries denote p-values < 
1x10-17.  
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Figure 4.S12. Non-random distribution for distance pruned set of genes.  
Genes were filtered such that no two genes were within 0.1cM of another. The remaining subset 
of genes was then tested for non-random distribution in diseases on the x-axis. The –log10 of the 
p-value is presented on the color scale and white entries denote p-values < 1x10-17. Results are 
largely similar to the original without filtering of nearby genes.  
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Figure 4.S13. PC3 and PC4 of all diseases disPCA.  
Similar to Figure 4.4 with data being presented for PC3 and PC4. A) PC1 accounts for 4.18% of 
the variance, while PC2 accounts for 4.08%. PC1 clusters celiac disease and SLE together, while 
PC2 separates inflammatory bowel diseases from other diseases and traits. B) The portion of 
variance explained by each PC is displayed. C) The weightings for genes on PC1 are displayed 
and ordered according to their weights. D) Similar to (C) where loadings are for PC2.  
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4.6 Tables  
PC Disease P-value* 
P-value 
(distance 
pruned)* 
1 Lupus erythematosus 1.59x10-6 3.0x10-8 
  Arthritis 1.72x10-6 >0.01 
  Connective tissue diseases 5.00x10-4 >0.01 
  Autoimmune diseases 2.6x10-3 2.05x10-6 
  Rheumatic Diseases 2.6x10-3 >0.01 
  Immune system diseases 6.5x10-3 2.2x10-5 
    
2 Gastroenteritis 5.79x10-13 2.92x10-9 
  Crohn's Disease 2.12x10-12 1.73x10-8 
  
Inflammatory bowel 
diseases 1.65x10-11 7.53x10-8 
  Fistula 4.00x10-9 1.37x10-7 
  Gastrointestinal diseases 3.49x10-8 7.16x10-8 
  Celiac disease 2.75x10-5 7.8x10-6 
  Multiple sclerosis 2x10-3 7x10-4 
  Skin diseases, genetic 2.3x10-3 8.1x10-3 
  Rheumatic diseases 6.4x10-3 2.3x10-3 
  Autoimune diseases 9.6x10-3 2.7x10-3 
* Bonferroni adjusted for multiple testing 
 
Table 4.1. Disease enrichment analysis for disPCA (Figure 4.1).  
Table shows disease enrichment results for all diseases significantly enriched with an adjusted p-
value < 0.01. The distance pruned p-values refers to disease enrichment after removing the latter 
out of a pair of genes that were within 0.1cM of each other.  
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PC Pathway FDR (q-value) 
1 Antigen processing and presentation 0.034 
  
Intestinal immune network for IgA 
production 0.042 
  Trk-A pathway 0.169 
  CK1 pathway 0.213 
  DREAM pathway 0.228 
  
Valine leucine and isoleucine 
biosynthesis 0.228 
  O-glycan biosynthesis 0.243 
  Folate biosynthesis 0.246 
   
2 NOD-like receptor signaling pathway <1x10-4 
  
Intestinal immune network for IgA 
production 0.074 
  Neurotrophin signaling pathway 0.165 
  Chemokine signaling pathway 0.195 
  Fc epsilon RI signaling pathway 0.232 
  Terpenoid backbone biosynthesis 0.232 
  JAK-STAT signaling pathway 0.238 
 
Table 4.2. Gene enrichment analysis for disPCA.  
Table shows pathways that are enriched in the disPCA analysis based on the GSEA analysis.  
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PC Pathway FDR q-value 
1 NOD-like receptor signaling pathway 0.006 
  
Local acute inflammatory response 
pathway 0.143 
   
2 Proteasome pathway 0.077 
  Th1-Th2 pathway 0.102 
  Proximal tubule bicarbonate reclamation 0.135 
  Adherens junction 0.142 
  RNA polymerase 0.171 
  CTLA-4 pathway 0.173 
 
Table 4.3. Gene enrichment analysis for disPCA without the HLA region.  
Table shows pathways that are enriched in the disPCA analysis based on the GSEA analysis after 
removing genes in the HLA and surrounding region.  
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Pairs of datasets of the same disease 
PC Ranked by Correlation p-value 
1 Physical 0.62 1.7x10-6 
  Genetic 0.69 3.6x10-8 
2 Physical 0.51 1.0x10-4 
  Genetic 0.31 0.0287 
mean(PC1,PC2) Physical 0.74 1.1x10-9 
  Genetic 0.67 8.4x10-8 
 
Table 4.S1. Comparison of loadings between disPCA with mapping based on physical or 
genetic coordinates.  
Loadings for the top 50 genes ranked by either a physical or genetic coordinates based disPCA 
were compared. ‘Correlation’ denotes the Pearson’s correlation coefficient with its significance 
denoted in the ‘p-value’ column. Rows denoted by ‘mean(PC1,PC2)’ indicate the correlation 
between the 50 genes with the largest average loading of PC1 and PC2.  
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Study Name Disease Obtained via 
Association 
Method Array 
Sample 
Size 
ALS 
Finland(Laaksovirta, 
Peuralinna et al. 2010) 
(ALS_Fin) ALS dbGaP Logistic regression 
Overlap 
between 
Illumina 
1M and 
CNV 370 973 
ALS Irish(Cronin, 
Berger et al. 
2008)(ALS_Irish) ALS dbGaP Logistic regression 
Illumina 
550k 432 
Duke 
Alzheimer's(Heinzen, 
Need et al. 2010) 
(Alz_Duke) 
Alzheimer's 
Disease 
http://humangeno
me.duke.edu/avail
able-datasets Logistic regression 
Illumina 
550 699 
GenADA (Li, Wetten et 
al. 2008)(Alz_GenADA) 
Alzheimer's 
Disease dbGaP Logistic regression 
Affymetrix 
400 1588 
WTCCC2 AS(Evans, 
Spencer et al. 2011) 
(AS_WT) 
Ankyolosing 
Spondylitis WTCCC Logistic regression 
Illumina 
1M 2732 
ADHD PGC(Neale, 
Medland et al. 2010) 
(ADHD_PGC) ADHD PGC Meta-analysis Imputation 5415 
Behcet's 
GWAS(Remmers, 
Cosan et al. 2010) 
(Behcets_GWAS) Bechet's dbGaP Chis-sq 
Illumina 
CNV 370 2493 
BMI Stampeed (Sabatti, 
Service et al. 
2009)(BMI_Stampeed) BMI dbGaP Linear regression 
Illumina  
CNV 370 5415 
BMI Sardinia(Scuteri, 
Sanna et al. 2007) 
(BMI_Sardin) BMI dbGaP Merlin 
Affymetrix 
500 1412 
CGEMS Breast 
Cancer(Hunter, Kraft et 
al. 2007) 
(BreastC_CGEMS) Breast Cancer dbGaP Logistic regression 
Illumina 
550 2287 
CIDR Celiac(Ahn, Ding 
et al. 2012) 
(CeliacD_CIDR) Celiac disease dbGaP Logistic regression 
Illumina 
660 2246 
NIDDK IBD(Duerr, 
Taylor et al. 2006) 
(CD_NIDDK) 
Crohn's 
disease dbGaP Chis-sq 
Illumina 
300 1028 
WTCCC CD( !The 
Wellcome Trust Case 
Control Consortium 
2007) (CD_WTCCC) 
Crohn's 
disease WTCCC Logistic regression 
Affymetrix 
500 3293 
Ischemic 
Stroke(Matarin, Brown 
et al. 2007) (IscStroke) 
Ischemic 
Stroke dbGaP Logistic regression 
Illumina 
300 485 
Major Depression 
GWAS(Boomsma, 
Major 
depression dbGaP Logistic regression 
Perlgen 
600k 3741 
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Willemsen et al. 2008) 
(MajDep) 
WTCCC2 MS(Sawcer, 
Hellenthal et al. 2011) 
(MS_WT) 
Multiple 
Sclerosis WTCCC Logistic regression 
Illumina 
1M 4055 
GeneMSA(Baranzini, 
Wang et al. 2009) 
(MS_GeneMSA) 
Multiple 
Sclerosis dbGaP Logistic Regression 
Illumina 
550 2000 
CIDR 
Parkinson's(Karamoham
ed, Golbe et al. 2005; 
Nichols, Pankratz et al. 
2005) (Parkin_CIDR) Parkinson's dbGaP Logistic regression 
Illumina 
CNV 370 1991 
CASP(Helms, Cao et al. 
2003; Nair, Stuart et al. 
2006; Nair, Duffin et al. 
2009) (Psor_CASP) Psoriasis dbGaP Chi-sq 
Perlgen 
600k 2825 
WTCCC RA ( !The 
Wellcome Trust Case 
Control Consortium 
2007) (RA_WTCCC) 
Rheumatoid 
arthritis WTCCC Logistic regression  
Affymetrix 
500 3481 
Schizophrenia 
GWAS(Suarez, Duan et 
al. 2006) 
(Schizo_GWAS) Schizophrenia dbGaP Chi-sq 
Affymetrix 
6.0 2659 
PGC 
Schizophrenia(Schizoph
renia Psychiatric 
Genome-Wide 
Association Study 
(GWAS) Consortium 
2011) (Schizo_PGC) Schizophrenia PGC Meta-analysis Imputation 21,856 
SLEGEN(Harley, 
Alarcon-Riquelme et al. 
2008) (SLE_SLEGEN) SLE dbGaP additive model 
Illumina 
300 297 
SLE GWAS(Hom, 
Graham et al. 2008) 
(SLE_GWAS) SLE dbGaP Chi-sq 
Illumina 
550 4651 
T2D Fusion(Scott, 
Mohlke et al. 2007) 
(T2D_Fusion) T2D dbGaP Logistic regression 
Illumina 
300 1706 
T2D 
Scandinavia(Saxena, 
Voight et al. 2007) 
(T2D_Scandinavia) T2D 
http://www.broad
institute.org/diabe
tes/scandinavs/typ
e2.html 
Cochran-Mantel-
Haenszel 
Affymetrix 
500 3000 
WTCCC2 UC(Barrett, 
Lee et al. 2009) 
(UC_WT) 
Ulcerative 
colitis WTCCC Logistic regression 
Affymetrix 
6.0 404 
VitGene(Jin, Birlea et 
al. 2010) (Vit_GWAS1) Vitiligo dbGaP Logistic regression 
Illumina 
610 4327 
Vitiligo GWAS2(Jin, 
Birlea et al. 2012) 
(Vit_GWAS2) Vitiligo Collaboration Logistic regression 
Illumina 
660 3632 
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Table 4.S2. Dataset attributes.  
Various attributes of datasets utilized in this study.  
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Replication 
PC Ranked by 
Correlatio
n p-value 
1 Replication 1 -0.056 0.7 
  Replication 2 0.28 0.049 
2 Replication 1  0.479 4.3x10-4 
  Replication 2 0.634 7.7x10-7 
mean(PC1,PC2) Replication 1  0.444 1.2x10-3 
  Replication 2 0.652 7.7x10-7 
 
Table 4.S3. Comparison of loadings between Replication Sets 1 and 2.  
Loadings for the top 50 genes ranked by either Replication Set 1 or Replication Set 2 were 
compared. ‘Correlation’ denotes the Pearson’s correlation coefficient with its significance 
denoted in the ‘p-value’ column. Rows denoted by ‘mean(PC1,PC2)’ indicate the correlation 
between the 50 genes with the largest average loading of PC1 and PC2. 
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PC Pathway FDR (q-value) 
1 
Intestinal immune network for IgA 
production 0.028 
  Antigen processing and presentation 0.057 
  Spliceosome 0.141 
  Inositol phosphate metabolism 0.156 
  Cell adhesion molecules 0.19 
  
2 NOD-like receptor signaling pathway 0.152 
  GH pathway 0.207 
  Insulin pathway 0.211 
  CardiacEGF pathway 0.213 
  IL2 pathway 0.226 
  NFAT pathway 0.236 
  Dorso ventral axis formation 0.236 
  IL2RB pathway 0.245 
  IGF-1 pathway 0.246 
 
Table 4.S4. Pathway enrichment after filtering nearby genes.  
Pathway enrichment was applied to a subset of genes that were located greater than 0.1cM from 
each other 
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